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1.1
CHARACTERISATION OF HYPOXIA RESPONSIVE ELEMENT
ACTIVITY UNDER ANOXIA IN BREAST CANCER CELLS: ROLE
OF HIF-1 AND ATF-4 K Ameri*1,2, CE Lewis1, B Burke1 and A L Harris2,
1Department of Pathology University of Sheffield,2 ICRF Medical Oncology
Unit, University of Oxford, UK
Areas of hypoxia or anoxia are hallmark features of malignant tumors. Novel forms of
cancer gene therapy have recently used hypoxia response elements (HREs), found in
or near the promoters of oxygen-regulated genes, to target reporter or therapeutic gene
expression to these low oxygen sites in solid tumors. When these cells are exposed to
hypoxia, a family of hypoxia-inducible factors (HIFs) are upregulated and bind/trans-
activate the HRE to trigger expression of the downstream gene. It was envisaged that
this would ensure transcriptional targeting only in hypoxic tumour sites and not else-
where in the body. However, there is now concern about the degree of normoxic
activity shown by such HREs as the commonly used one from the PGK-1 gene.
Moreover, the activity of many HREs in complete anoxia has yet to be demonstrated.
This is important as maximal HIF-1 protein levels and DNA binding occur at 0.5%
oxygen in hepatoma cells, but drop markedly at 0% O2, suggesting that activity of
HRE-driven DNA constructs could be compromised under anoxia (if this involves
HIF-1).
In order to design HRE-gene constructs optimised to: (i) be active only in the severe
hypoxia found in solid tumours, and (ii) maintain high level activity under complete
anoxia in tumours, we have characterised the ability of HREs from the PGK 1, EPO
and aldolase genes, to drive luciferase (LUC) expression in MCF-7 cells under
normoxia (21% O2), hypoxia (1 and 0.5% O2) and complete anoxia (0% O2). We then
compared this with the activity of an anoxia-responsive VL30 element (SARE) in
hypoxia/anoxia, and point mutated this to elucidate the role of the HIF-1 consensus
binding site and its immediate flanking sequence in the anoxic induction of HREs in
human cells. Our results show the presence of a HIF-1 consensus (CGTG) to be essen-
tial in both the anoxic as well as the hypoxic response, and that a short sequence imme-
diately preceding this determines the magnitude of anoxia responsiveness.
Immunoblotting studies revealed upregulation of HIF-1, HIF-2, ATF-1 and ATF-4
levels in 0.5 and 1%O2 (compared to normoxia) in MCF-7 cells. Whereas HIF-1 and
ATF-1 dropped between 0.5 and 0% O2, ATF-4 levels were seen to markedly increase.
Two slightly different molecular weight forms of HIF-1 were present in MCF-7 cells
under 1 and 0.5%O2, whereas in anoxia mainly the higher molecular weight HIF-1 was
evident. We are currently investigating (i) whether the latter represents a phosphory-
lated form of HIF-1, and (ii) the functions of this and ATF-4 under anoxia. To date, our
ATF-4 over-expression studies have indicated that ATF-4 may be involved in the tran-
scriptional shutdown of certain promoter elements seen under anoxia, and that the
SARE is protected from this by a mechanism that has yet to be defined.
1.2
HYPOXIA-INDUCIBLE TRANSCRIPTION FACTORS IN
MACROPHAGES: IMPLICATIONS FOR OPTIMISATION OF
THERAPEUTIC DNA CONSTRUCTS FOR A NOVEL, MACROPHAGE-BASED
CANCER GENE THERAPY B Burke*1, K Ameri1,2, N Tang1, D Tazzyman1, M
Wells1, A Harris2 and C Lewis1, 1Dept of Pathology, University of Sheffield,
Sheffield S10 2RX, 2ICRF Medical Oncology Unit, University of Oxford, UK
The presence of areas of extremely low (hypoxia) or no (anoxia) oxygen is a hallmark
feature of many types of solid human tumour. We have shown recently that
macrophages accumulate in large numbers in avascular, hypoxic sites in various forms
of malignant human tumour. Moreover, they upregulate a family of hypoxia-inducible
transcription factors called HIFs which then bind to specific enhancers near oxygen-
regulated genes, called hypoxia response elements (HREs), to trigger gene expression.
These findings led to the suggestion that macrophages could be used as cellular
vectors to target therapeutic genes to hypoxic tumour sites. In our work on this to date
(Griffiths et al., Gene Therapy, 2000, 7:255), we have shown that macrophages aden-
ovirally transduced with HRE-driven gene constructs migrate into hypoxic areas of
tumour spheroids in vitro, where the HIFs made by the cell bind and transactivate the
construct, and the therapeutic gene is expressed. This approach should ensure effec-
tive delivery to, and expression in, hypoxic tumour sites (which are relatively drug
and radiotherapy resistant) in vivo. To date, a trimer of the HRE from the phospho-
glycerate kinase-1 (PGK-1) gene has been used in these constructs, as this has been
shown to be effective in primary macrophages under hypoxia. We report here on our
attempts to optimise the efficacy of such hypoxia-driven constructs, and to assess a
range of other HREs for efficacy, specifically in macrophages.
First, we have examined the effects of hypoxia on the levels of various transcrip-
tion factors (HIF-1, HIF-2 (EPAS-1), Egr-1, and activating transcription factors
(ATFs) 1, 2 and 4) in both the human macrophage-like cell line, Monomac 6 (MM6),
and primary, monocyte-derived macrophages. Western blotting studies showed that
HIF-1 and EPAS-1 proteins are induced by hypoxia in these cells, while levels of
ATFs 1,2 and 4 and Egr-1 remained low or unaffected. This confirmed that HREs are
currently the most appropriate response element to use for maximal hypoxia-
inducibility of DNA constructs in macrophages.
We then compared the efficacy of various known HRE’s (ie. derived from different
hypoxia-inducible genes) in driving luciferase expression in transiently transfected
(electroporated) MM6 cells under hypoxia. The highest levels of induction were
observed using constructs containing either a trimer or a hexamer of the murine PGK-
1 HRE. A trimer of the human erythropoietin (EPO) HRE was also hypoxiainducible
in these cells. This accords well with the finding that macrophages express EPO in
vivo. Little or no hypoxic induction was obtained using constructs carrying the
anoxia/hypoxia responsive rat VL30 retrotransposon element.
1.3
OVER-EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH
FACTORS-C & -D (VEGF-C & -D) ARE ASSOCIATED WITH POOR
SURVIVAL IN COLORECTAL CANCER (CRC) JD White*, DD Kosuge, PW
Hewett, TA McCulloch1, J Carmichael & J Murray, Cancer Research
Campaign Dept of Clinical Oncology & 1Pathology Dept, Nottingham City
Hospital, Nottingham, UK
Introduction Lymphatic involvement is important in the prognosis of colorectal
cancer (CRC); however the relative impact of angiogenesis and lymphangiogenesis
on prognosis of tumours is unclear. VEGF-C & -D are members of the VEGF family
of angiogeneic growth factors. While VEGF-C is angiogeneic, expression also been
associated with lymphatic metastasis in several cancers. VEGF-D is expressed in
normal bowel mucosa and is also angiogenic, however the expression of VEGF-D in
cancers is not well documented. One of the receptors for VEGF-C, VEGFR-3 is
mainly expressed on lymphatic endothelial cells in the adult, thus VEGF-C may be
involved in lymphatic development. We have examined the relationship between
VEGF-C &-D expression and survival in CRC.
Methods Immunohistochemistry with polyclonal antibodies for VEGF-C &-D
was performed on 84 cases of CRC and 20 adenomas. The sections were grouped
according to high or low staining intensity. Associations with other prognostic
features and impact on disease free (DFS) & overall survivals (OS) were assessed.
Results All adenomas showed low grade staining for both ligands. With progres-
sion from adenoma to advancing Dukes’ stage the frequency of high-grade expression
increased significantly for VEGF-C and VEGF-D. Amongst CRC samples high-grade
expression was seen in 29% stained for VEGF-C and 52% for VEGF-D. High-grade
expression for both ligands tended to coincide in the same sections (p = 0.032).
Mucinous differentiation was noted in 7/8 cases with grade high VEGF-D expression.
Lymphatic metastases, were seen significantly more frequently in those with high
grade VEGF-D expression (48% vs 18%) corresponding figures for VEGF-C (63% vs
22%). For VEGF-C vascular invasion was seen in 6/9 high-grade compared to 16/73
low-grade tumours (p = 0.007). Increased expression of VEGF-D was significantly
associated with increased frequency of deaths during follow up and significantly
shorter DFS and OS. For VEGF-C, recurrences were significantly associated with
high-grade expression, however the grade of VEGF-C expression did not predict type
of recurrence. High-grade VEGF-C expression was also associated with a trend to
worse OS and shorter DFS.
Conclusions Expression of VEGF-C &-D increases significantly with progression
from adenoma to invasive carcinoma and are both associated with decreased survival.
The mechanistic significance of our observations remains to be clarified.
1.4
TUMOUR VASCULAR TARGETING USING A NOVEL ANTI-
VASCULAR ENDOTHELIAL CELL GROWTH FACTOR (VEGF)
SCFV ANTIBODY SP Cooke*, GM Boxer, DIR Spencer, L Lawrence, RB
Pedley, KA Chester and RHJ Begent, Department of Oncology, RFH & UCL
Medical School, Royal Free Campus, London NW3 2PF, UK
Successful antibody targeted therapy of solid tumours has been limited by a number of
factors including poor penetration of therapeutic agents to all tumour cells; antigenic
heterogeneity and the ability of tumour cells to become both chemo- and radio-
resistant. An attractive approach is to target cytotoxic agents to the vasculature of the
tumour rather than to the tumour cells themselves as restriction of one vessel is known
to cause the destruction of many hundreds of tumour cells. Vascular endothelial
growth factor (VEGF) is an angiogenic growth factor that is the primary stimulant of
the vascularisation of solid tumours. A single-chain Fv (scFv) antibody (LL4) was
selected against human VEGF165 (VEGF-A) from a phage display library and subse-
quently screened by immunohistochemistry (IHC) for binding to blood vessel
endothelium. Detailed analysis of the reactivity of LL4 was then carried out to deter-
mine its specificity for tumour blood vessel endothelium. This study involved further
IHC screening against a panel of both normal and neoplastic human tissue sections
and samples from non-tumour bearing mice. LL4 showed weak staining of some
normal tissues, but strong reactivity with tumour sections demonstrating binding to
VEGF in malignant cells, stroma and endothelial cell surfaces. In order to quantitate
the specificity of the scFv for tumour blood vessel endothelium 125I-labelled LL4 was
injected into nude mice bearing LS174T colorectal xenografts. Tumour and normal
tissues were excised 1 hr and 3 hr post injection, formalin-fixed, sectioned and
exposed to autoradiographic emulsion (6 weeks). Grains associated with blood vessel
endothelium were counted and compared with those obtained from control mice
injected with a control scFv anti-CEA antibody. Autoradiography demonstrated selec-
tive uptake and retention of LL4 in tumour xenograft compared to both the anti-CEA
control (p=0.0001) and normal tissues (p=0.0001). Finally, to confirm that LL4 bound
the VEGF:receptor complex, surface enhanced laser desorption ionisation affinity
mass spectrometry (SELDI-AMS) was used to analyse the interaction of immobilised
LL4 with recombinant VEGF-A, both free, and bound to its cognate receptor (VEGF-
R2/KDR). Results showed definitively that LL4 was specific for VEGF-A both in its
free state and when was complexed with its receptor. This study demonstrates specific
targeting of the VEGF:receptor complex on tumour vascular endothelium by an engi-
neered scFv antibody selected from a phage library.
This work was funded by the Cancer Research Campaign.
British Journal of Cancer (2000) 83(Suppl 1), 11–28
© 2000 Cancer Research Campaign
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1.5
MODIFICATION OF HUMAN TUMOUR BLOOD FLOW USING
PENTOXIFYLLINE, NICOTINAMIDE AND CARBOGEN A Sibtain*1,
SA Hill2, KA Goodchild1, N Shah1, MI Saunders1, PJ Hoskin1, 1Marie Curie
Research Wing, Mount Vemon Hospital, Northwood, HA6 2RN, 2Gray
Laboratory Cancer Research Trust, Northwood HA6 2JR, UK
Introduction Both nicotinamide and pentoxifylline used as single agents, when
combined with carbogen breathing, result in an increase in relative red cell flux as
measured by laser doppler in human tumours. Since these agents have different puta-
tive mechanisms of action, a synergistic action on blood flow might be expected.
Aim To assess the effect of combining oral nicotinamide, oral pentoxifylline and
carbogen gas (2% CO2, 98% O2) breathing on human tumour blood flow. Methods and
Materials: Microregional red blood cell flux was measured in accessible tumour
nodules using laser Doppler microprobes in 10 patients with histologically proven
malignancy. Patients received single oral doses of nicotinamide 40 mg/kg and pentox-
ifylline 1200 mg two hours before a ten minute period of carbogen gas breathing,
corresponding to peak plasma concentrations of these drugs. Blood flow in up to six
microregions in each tumour was measured for 30 minutes, recording pre-, during and
post-carbogen breathing for ten minutes each.
Results The blood flow in 57 microregions were analysed and the mean blood
flow was deduced. A mean relative increase in blood flow of 1.20 (+/–0.08, 95% CI)
was observed after 8 minutes of carbogen breathing. This compares to relative
increases of 1.4(+/–0.39, 95% CI) after nicotinamide alone with carbogen and
1.15(+/–0.10,95% CI) after pentoxifylline alone with carbogen. These differences are
not statistically significant (p>0.05). The blood flow returned to the pre-carbogen
level within 10 minutes of cessation of carbogen breathing and no patient in any group
demonstrated a reduction in flow.
Conclusion A combination of pentoxifylline, nicotinamide and carbogen produces
an increase in human tumour blood flow, similar to that observed when each of the
drugs are used alone with carbogen breathing. The absence of synergism between
pentoxifylline and nicotinamide suggests that despite different modes of action, a
ceiling for flow enhancement may exist in tumours of around 20%.
1.6
ENHANCING TUMOUR VASCULARITY AND BLOOD FLOW DOES
NOT INCREASE METASTASIS IN A MODEL OF COLORECTAL
CANCER P Mathur*1, MM Davies1, P Carnochan2, TG Allen-Mersh1,
1Department of Surgery, Imperial College School of Medicine, Chelsea &
Westminster Hospital, London, SW 10 9NH, 2Institute of Cancer Research,
Sutton, UK
Background Primary tumour vascularity correlates with risk of metastasis but it is not
clear whether this is because increased vascularity improves tumour cell access to the
circulation or because both tumour vascularity and metastasis are associated with the
same oncogene mutations. To assess this we examined metastasis, in the same tumour
cell line, where tumour vascularity was increased by either primary tumour interstitial
or systemic infusion of basic Fibroblast Growth Factor (bFGF).
Methods Subcutaneous DHD/K12/Tr (rat colonic adenocarcinoma) tumours were
infused either interstitially or systemically with bFGF. Control animals received
saline. On day 28 the primary tumours were excised to allow vascularity (vessel count
& vessel volume), blood flow (autoradiography) and tumour growth (tumour volume
& proliferation index) assessment. The animals were recovered to allow metastasis
growth and sacrificed two months later. At this stage lungs were excised, weighed and
examined for metastases and extra-pulmonary metastases noted.
Results
Infusion Vascularity† Tumour Volume ProL Index Rats with
(n) Count/mm2 Volume% mm3† %† lung mets (n)
saline 35 3.6 1150 12 9
(17) (34–36) (2.5–4) (1022–1277) (9.4–15)
interstitial 65 5.9 2268 21 11
bFGF (18) (62–77) (5.8–6) (1882–2416) (19–23)
p* 0.008 0.004 0.05 0.03 0.3
saline 10 1.8 359 5 7
(13) (10–20) (1.3–2) (125–515) (4–6)
systemic 36 6.4 611 14 9
bFGF (15) (31–56) (5.5–7) (469–628) (10–16)
p* 0.009 0.009 0.0758 0.0367 0.87
[*Mann Whitney-U test; † Median (IQR); ‡Repeated measures ANOVA].
There were also significant increases in vessel length density (interstitial: p=0.0001;
systemic: p< 0.0001) and blood flow (interstitial: p=0.0005; systemic: p<0.0001‡) .
There was no difference in lung weights (gms)(Interstitial: p=0.3; Systemic: p=0.24)*.
Conclusion There were significant increases in primary tumour vascularity, blood
flow and growth with both interstitial and systemic bFGF infusion, however this was
not associated with increased metastasis either when the primary tumour only (intersti-
tial) or when the metastatic site (systemic) was exposed to bFGF. These results suggest
that the relation between vascularity and metastasis does not result from increased
tumour cell access to the circulation or increased bFGF at the metastatic site.
1.7
COMBRETASTATIN A4 PHOSPHATE (CA4P) TARGETS
VASCULATURE IN ANIMAL AND HUMAN TUMOURS Galbraith
SM*, Taylor NJ, Maxwell RJ, Lodge M, Tozer GM, Baddeley H, Wilson I,
Prise VE, Rustin GJS, Mount Vernon Hospital, Northwood, Middlesex, UK
CA4P dramatically reduces blood flow in animal tumours at non-toxic doses, causing
haemorrhagic necrosis.
Aim To determine the dose and time response of CA4P on tumour blood flow in
rats and humans.
Methods The absolute blood flow of tumours and normal tissues in BD9 rats
bearing P22 carcinosarcomas was measured using radiolabelled iodoantipyrine (IAP).
Serial dynamic MRI scans were performed on the same tumour model to enable
comparison of the MRI and IAP techniques. Patients in the C RC Phase 1 trial of
CA4P also had serial dynamic MRI scans using the same protocol as the in-vivo
experiments. 30 dynamic images were obtained at 11.9s intervals prior to, during and
after intravenous injection of Gadolinium-DTPA. The MRI sequence used was a 3
slice spoiled gradient echo, with echo time 9 ms, repetition time 80 ms, flip angle 70°
and slice width 10 mm. Regions of interest (ROIs) were drawn around whole tumours
and in skeletal muscle. The signal intensity/time curve for these ROIs was analysed
using a pharmacokinetic model1, and an assumed arterial input function. 2 parameters,
Ktrans (transfer constant)1 and AUC2 (area under the curve) derived from this analysis
were used as a measure of blood flow.
Results Tumour blood flow measured by IAP in rats was reduced by 88% at 10
mg/kg 6 hrs post CA4P, and by 20% at 24 hrs. At 100 mg/kg blood flow reduced by
99% at 6 hrs and 24 hrs. In the same tumour model the MRI parameters Ktrans and
AUC were reduced by 71% and 65% respectively at 10 mg/kg after 6 hrs, and by 33%
and 36% at 24 hrs. At 100 mg/kg Ktrans and AUC were reduced by 83% and 90%,
maintained at 24 hrs. r2=0.82 for correlation of Ktrans or AUC and IAP data.
12 of 22 patients treated with 5 to 114 mg/m2 CA4P had serial MRI scans. No
significant changes were observed below 52 mg/m2. In 7 patients treated at 88 and 114
mg/m2 mean Ktrans and AUC were reduced by 41%* and 36%* respectively at 6 hrs
post CA4P, and by 19% (NS) and 24%* at 24 hrs. The maximal reduction seen was
84% (Ktrans) in a patient at 88 mg/m2. No significant changes in Ktrans or AUC were
seen in muscle. 4 of these 7 patients had pain in the tumour site after each dose of
CA4P The dose limiting toxicity was ataxia at 114 mg/m2. (* =p<0.05)
Conclusions There was a high degree of correlation between absolute blood flow
changes measured by IAP and the MRI parameters (. The time course of action of
CA4P is similar in rat and human tumours. CA4P reduces Ktrans and AUC in human as
well as animal tumours at doses below the DLT.
1 Tofts PS, Brix G, Buckley DL et al (1999) J Magn Reson Imaging 10: 223–232
2 Evelhoch JL (1999) J Magn Reson Imaging 10: 254–259
1.8
STUDIES ON THE MECHANISM OF ACTION OF THE VASCULAR
TARGETING AGENT COMBRETASTATIN A-4 PHOSPHATE
C Kanthou* & GM Tozer, Tumour Microcirculation Group, Gray Laboratory
Cancer Research Trust, PO Box 100, Mount Vernon Hospital, Northwood,
Middlesex, HA6 2JR, UK
Combretastatin A-4 phosphate (CA-4-P) is in clinical trials as a promising antivas-
cular agent that targets the microtubule cytoskeleton by binding at the colchicine locus
of tubulin and altering its polymerization dynamics. Previous studies demonstrated
that CA-4-P exhibits selective toxicity toward the tumour vasculature and causes its
selective shutdown in animal models (Dark et al, 1997, Cancer Res 57, 1829; Tozer et
al, 1999, Cancer Res 59, 1626).
We investigated CA-4-P’s mechanism of action in cultured human umbilical vein
endothelial cells (HUVECs). The state of tubulin polymerization was evaluated by
extracting dimeric and polymeric forms of tubulin followed by western blot analysis. In
control confluent HUVECs, approximately 70% of the tubulin existed in a polymerized
form. CA-4-P (0.1 mM; 30 min) caused total tubulin depolymerization. Vascular
smooth muscle cells and breast carcinoma MDA-231 cells were significantly less
sensitive to CA-4-P as about 20% of their tubulin remained polymerized after treat-
ment with CA-4-P (1–100 mM; 60 min). CA-4-P caused rapid (within min) HUVEC
retraction and membrane blebbing, a manifestation of toxicity associated with apop-
tosis, previously shown to be induced by CA-4-P (Iyer et al, Cancer Res, 1998, 58
4510). Cytoskeletal alterations affecting the dynamics of actin are thought to be associ-
ated with membrane blebbing and changes in endothelial function such as vascular
permeability. Stress stimuli that disrupt microtubules are known to activate actin reor-
ganization via signals through the GTP-binding protein, Rho. We investigated the
involvement of actin and Rho in CA-4-P mediated morphological changes. Confluent
HUVECs treated with CA-4-P in the presence or absence of the Rho kinase inhibitor
HA1077 were fixed, permeabilized and stained with Texas Red-conjugated phalloidin.
In control cells actin microfilaments were predominantly found along the cell margin
with some fine actin filaments traversing the cells. CA-4-P induced the formation of
stress fibres across the cell body and cells retracted forming intercellular gaps.
Additionally a significant proportion of cells exhibited a “blebbing” morphology in
which F-actin accumulated in the bleb perimeters and also formed a dense spherical
network in the cytoplasm. Pre-incubation with HA1077 abolished CA-4-P-mediated
blebbing as well as stress fibre formation. Pre-treatment with the myosin light chain
kinase inhibitor ML7 or the myosin ATPase inhibitor BDM led to a significant increase
in the proportion of blebbing cells in response to CA-4-P suggesting that this pheno-
type resulted from a misassembly of actomyosin stress fibres. These data suggest that
CA-4-P targets endothelial microtubules and regulates signals involved in the reorgani-
zation of the actin cytoskeleton via activation of Rho and other pathways.Oral Presentations 13
1.9
TUMOUR ERADICATION BY COMBINED ANTIBODY-DIRECTED
AND ANTIVASCULAR THERAPY RB Pedley*1, SK Sharma1, G
Boxer1, AA Flynn1, R Boden1, R Watson1, J Dearling1, SA Hill2, CJ Springer3
and RHJ Begent1, 1Oncology Dept, RF & UCLMS, London NW32PF; 2Gray
Lab Research Trust, HA62JR; 3ICR, SM25NG, UK
Common solid tumours contain well- and poorly-vascularised regions, each posing
different problems for therapy. Using phosphor image analysis we have shown that
antitumour antibodies localize therapy efficiently in well perfused outer areas of the
tumour, but less so in poorly perfused areas containing radio- and chemo-resistant
hypoxic cells. The addition of a complementary or synergistic therapy is therefore
required, and antivascular agents offer an attractive approach. We have studied two
antivascular agents, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and combreta-
statin A4-P (CA4-P), in combination with antibody-targeted therapies, using
colorectal xenograft models. While possessing different modes of action, both drugs
caused selective shut-down of tumour vessels leading to hemorrhagic necrosis of all
but an outer rim of well-vascularized cells, but do not affect subsequent tumour
growth. Radioimmunotherapy alone (7.4–18.5 MBq 131I-anti-CEA antibody)
produced no cures, but when combined with either DMXAA (27.5 mg/kg) or CA4-P
(200 mg/kg ´ 2) the tumours were eradicated in 85% and 90% of mice respectively.
When DMXAA was combined with Antibody-directed Enzyme Prodrug Therapy (25
U CPG2, 1500 mg/kg CMDA prodrug), tumour growth inhibition was again signifi-
cantly enhanced with no increase in toxicity. Both antivascular agents are in Phase I
trials, and we are currently optimizing these approaches for combined therapy in the
clinic.
Supported by the Cancer Research Campaign.
2.1
RATIONAL SELECTION OF ANTISENSE KIRSTEN RAS
OLIGONUCLEOTIDE BY MAPPING ACCESSIBLE SITES WITH
RIBONUCLEASE H PJ Ross*1,2, HJN Andreyev1,2, M George1, F di Stefano1,
D Cunningham2, and PA Clarke1, 1CRC Centre for Cancer Therapeutics,
Institute of Cancer Research, and 2Gastrointestinal Unit, The Royal Marsden
Hospital, Downs Road, Sutton, SM2 5PT, UK
Kirsten ras (Ki-ras) mutations are frequently observed in colorectal cancers and asso-
ciated with an increased risk of recurrence and reduced odds of survival. Codon 12 is
the most frequent site for Ki-ras mutations, however we found that antisense (AS)
oligonucleotides (ODN) complimentary to such mutations were of limited efficacy.
Therefore, an AS Ki-ras ODN was rationally selected. Ribonuclease H (RNase H)
cleavage sites were mapped on 3¢-labelled Ki-ras exons 1–3 mRNA incubated with a
library of random sequence 17-mer ODN and E. coli RNase H. This assay identified 2
highly accessible sites: nucleotides 380–401 and 413–422. Nucleotides 380–401
correlated with a computer and ribonuclease predicted hairpin loop. Ki-ras mRNA
was measured in the human colon adenocarcinoma SW480 cell line after transfection
with a panel of ODN targeting accessible sites identified by the screening protocol.
The most effective ODN, PR4, resulted in greater than 90% reduction in Ki-ras
mRNA 24 hours after treatment of the cells. In contrast, a scrambled sequence control
ODN had no effect on Ki-ras mRNA expression. Neither AS nor scrambled ODN
altered the expression of GAPDH mRNA. Inhibition of Ki-ras protein expression was
observed 72 hours after treatment with PR4. No effect on the expression of N-Ras
protein was detected. In addition, following repeat treatments of human colon cancer
cells with PR4 phosphorylation of mitogen activated protein kinase was reduced.
Such a reduction was not observed after treatment of human colon cancer cells with
scrambled oligonucleotide. Proliferation of human colon cancer cells treated with PR4
was reduced compared to a scrambled ODN but no specific cell cycle effects were
detected. VEGF secretion by human colon cancer cells was reduced by 44% following
treatment with PR4 compared to scrambled ODN (p=0.012).
A rationally designed AS Ki-ras ODN significantly reduced Ki-ras mRNA and
protein expression. AS inhibition of Ki-ras in human colon cancer cells reduced
proliferation and VEGF secretion. These findings justify further evaluation of the
activity of ODN PR4.
2.2
INHIBITION OF THE RECEPTOR GENE EXPRESSION BY A
NOVEL ANTI-GENE APPROACH *PW Hewett1, EL Daft1, C
Laughton2 and JC Murray1, CRC Academic Dept of Clinical Oncology, City
Hospital, and 2Cancer Research Labs; Dept. of Pharmaceutical Sciences,
University of Nottingham, Nottingham, UK
We are developing anti-gene approaches to block tumour angiogenesis through the
targeted formation of triplex DNA. The Tie receptor tyrosine kinases (Tie-1 and Tie-
2) are largely restricted to endothelium and play a critical role in angiogenesis,
vascular remodelling and maintenance of vessel integrity. Disruption of the Tie recep-
tors has been shown to inhibit angiogenesis and reduce tumour growth as a conse-
quence. Based upon our recent characterisation of the 5¢ regulatory regions of the
human tie genes, we have identified several suitable conserved sequences that could
be targeted to disrupt transcription through DNA triplex formation. In order to test this
paradigm we have focused on the human Tie-1 promoter which contains two ideal ~20
bp homopurine sequences. These sequences represent tandem ets transcription factor
binding sites (EBS) which we have shown through the use of mutated promoter-
reporter constructs are essential for promoter activity. Using plasmid binding and
electrophoretic mobility shift assays we have demonstrated specific triplex forming
activity of a range of anti-parallel homopurine TFOs (Kd<10–7M) targeted to these
sequences at 37°C and physiological pH in the presence of 10 mM Mg2+. In order to
determine the activity of candidate TFO on tie-1 promoter activity, TFO were incu-
bated with tie-1 luciferase reporter constructs overnight at 37°C (pH 7.0) in the pres-
ence of 10 mM Mg2+. Reporter constructs were then co-transfected with a CMV
control promoter into endothelial cells and their activity determined by dual luciferase
assays. Candidate TFO targeted to the two EBS were found to inhibit up to 60% of
promoter activity in comparison with control oligos. As the formation and stability of
these DNA triplexes decreases in the presence of physiological (~150 mM) K+ ion
concentrations we are examining the potential of partially phosphorothioate-linked
TFO to overcome this problem in order to assess their activity on endogenous tie-1
expression. As Ets transcription factors are important in the regulation of a number of
endothelial-restricted genes that contain similar multiple EBS motifs this strategy may
have broad applicability to cancer and a number of conditions involving inappropriate
angiogenesis or endothelial dysfunction.
This work is supported by the Cancer Research Campaign
2.3
ADENOVIRAL TRANSFER OF P53 AND P16INK4A RESULTS IN
PANCREATIC TUMOUR REGRESSION P Ghaneh*1, W Greenhalf1,
M Humphreys1, D Wilson2, N Lemoine3, JP Neoptolemos1, 1Dept of Surgery,
Liverpool University, Daulby Street, UK, 2Introgen Therapeutics, Texas, USA,
3ICRF, Hammersmith Hospital, London, UK
Background Pancreatic cancer has a very poor prognosis as most patients present
with advanced disease. Current regimens of chemoradiation are only moderately
effective. Novel approaches to treatment are required. A high proportion of pancreatic
cancers are associated with loss of function of key cell cycle control genesp16INK4a and
p53. Previous work has shown p16INK4a and p53 gene therapy to inhibit pancreatic
tumour cell growth in vitro. The aim of this study was to demonstrate regression of
pancreatic tumours in vivo following transfer of wild type p16INK4a and p53 genes.
Methods Replication deficient recombinant adenoviruses which expressed wild-
type p53 or p16INK4a under the control of a CMV promoter and SV40 polyadenylation
signal were used for gene transfer to tumours. An identical vector expressing
luciferase was used as the control. The human pancreatic cancer cell line MIAPACA-
2 was used to generate subcutaneous tumours in 8-week old female nunu mice. Each
mouse received an injection of 1 ´ 107 cells into each flank. Tumours were left to
develop for four weeks. Each tumour then received one injection of 5 ´ 1011 virus
particles for three consecutive days. Tumours were removed from a single animal in
each group 24 hours after the last injection for expression analysis. RT-PCR was used
to amplify the transduced gene in tumours. Tumour volume was measured twice a
week until the mice were sacrificed at 3 weeks. Treatment groups (consisting of 6
animals with 12 tumours) received intratumoural injections of virus expressing either
luciferase, p53 alone or p16INK4a alone.
Results Wild-type p16INK4a and p53 RNA expression in the tumours was demon-
strated using RT-PCR. There was a significant difference in tumour volume change
between the treatment groups and the control group p<0.01 (Mann Whitney U), but
not between groups with treated tumours.
Conclusions Transfer of wild-type p16INK4a and p53 genes produced significant
regression of tumours in this animal model. These results indicate a role for tumour
suppressor gene therapy in the treatment of pancreatic cancer.14 Oral Presentations
2.4
NOVEL APPROACHES TO DESTROY MINIMAL RESIDUAL
CANCER IN THE MUSCLE BED RE Oakley*1, E Phillips1, D Wilson2,
and M Partridge1, 1Maxillofacial Unit/Oncology, Kings College Hospital,
London SE5 8RX, UK, 2Introgen Therapeutics Inc, 2250 Holcombe
Boulevard, Houston, Texas 77030, USA
Gene transfer offers the possibility of novel therapies for head and neck squamous
tumours. Since all adjuvants are most successful in the minimal residual disease
setting, one potential application for these approaches is to eliminate nests of tumour
which persist at the surgical margins after treatment. To date, most preclinical studies
using adenovirus-mediated gene delivery have used subcutaneous rodent tumour
models. However, residual tumour is frequently present in the muscle bed and it may
be more difficult to transduce tumour cells at this site. The effect of 3 isogenic vectors,
AD5CMVp53, Ad-bgal and Ad-empty, on tumour cell proliferation was determined
by in vitro growth assay. A rodent model of minimal residual cancer in the muscle bed
was established by implanting murine squamous cell carcinoma cells, harbouring a
p53 gene mutation, into the muscle of 7–8-week-old syngeneic hosts. Subcutaneous
tumours similar to those used in earlier preclinical studies were created over the dorsal
flanks as comparitors. Nests of tumour were apparent 4 days after inoculation.
Tumour nests in the muscle bed (minimum 6 mice per group) were injected with aden-
oviral particles on days 4, 7 and 9, with 5 ´ 1010 vp Ad5CMVp53, Ad-bgal or Ad-
empty, and histological examination performed on day 11. In vitro transduction of
cells following infection with Ad-bgal approached 100% and 5 ´ 1010 vp
Ad5CMVp53 significantly reduced tumour-cell growth and induced apoptosis.
Expression of the transgene was demonstrated by reverse transcription-polymerase
chain reaction and Western blotting. Expression of bgal was detected by X-gal
staining in approximately 20% of the cells within subcutaneous tumours, although the
frequency of tumour cell transduction was much lower when treating nests of tumour
in the muscle bed. Ad5CMVp53, delivered by direct intratumoural injection, had no
effect on tumour cell progression in the rodent model of residual cancer in the muscle
bed. These data show that it is feasible to develop rodent models of minimal residual
cancer in syngeneic hosts. However, the present schedule utilising Ad5CMVp53 was
not effective and the most likely explanation, based on the pattern of bgal expression,
is that insufficient vector reaches the tumour nests in the muscle. These studies high-
light the need to improve delivery of adenoviral-mediated gene transfer to muscle
tissues, or to use combination therapies, without overlapping toxicities to increase
selective and specific tumour cell killing.
2.5
FINE NEEDLE ASPIRATION CYTOLOGY OF BREAST CANCERS
YIELDS SUFFICIENT MATERIAL TO MONITOR P53 BY WESTERN
BLOTTING HM-L Ball1, TR Hupp2, JP Blaydes2, NM Kernohan2, AM
Thompson*1, 1Departments of Surgery & Molecular Oncology and Molecular
& Cellular Pathology, University of Dundee DD1 9SY, UK
Fine needle aspiration (FNA) cytology is routinely used in the diagnosis of breast
cancer as the least invasive method of in vivo breast cancer sampling. While FNA has
been used for PCR studies, we sought to assess the feasibility of using FNA as a tool
for monitoring functional p53 protein biochemistry (and p21 and p27, downstream
effectors of p53) in vivo. P53 appears to be important in the pathogenesis of breast
cancer and in the response of cancers to therapy; p53 status is now entering the clin-
ical arena in clinical trials as the basis for treatment selection and as a therapeutic
avenue.
For each of 14 histologically proven breast cancers, preoperative FNA (10 passes
of a 19 g needle), specimen FNA (10 passes of a 19 g needle taken at immediate
pathology cut-up) and frozen cancer tissue were lysed to extract protein for western
blot analysis. Blots were probed with DO12 (which recognises a cryptic epitope in the
core domain of p53) for absolute levels of p53 and for p53 phosphorylation sites using
DO1 (recognising the N-terminus influenced by phosphorylation of serine 20) and
FP3 (for serine 395 phosphorylation). Samples were also probed for p21 and p27
using in-house antibodies.
The protein extracted from the FNA samples was sufficient for at least five western
blots. Using DO12, p53 protein was present in 11/14 cancers. Using DO1, 10/14
cancers were positive and with FP3 1/14. For target genes of p53, 9/14 cancers were
p21 positive, but p27 detected in only 1/14. Analysis did not differ between the preop-
erative and postoperative FNA samples for any of the 14 cancers, suggesting intraop-
erative handling did not influence the p53 epitopes or downstream genes examined.
However, p53 degradation products were observed in the frozen cancer samples.
FNA in vivo yields adequate protein for western blotting which could be used to
monitor p53 activity during anticancer treatment. Furthermore, FNA studies of p53
may provide a more appropriate assessment of p53 function than using frozen tissue
samples.
2.6
USE OF O2-REGULATED BACTERIAL TRANSCRIPTION FACTORS
TO TARGET GENE EXPRESSION TO HYPOXIC SITES IN
TUMOURS SG Sumner*1, J Green2, S Naylor3 and CE Lewis1, Departments
of 1Pathology, and 2Molecular Biology and Biotechnology, Univ. of Sheffield,
and 3Oxford BioMedica, Oxford Science Park, Oxford OX4 4GA, UK
Recent advances in cancer gene therapy have involved the use of various molecular
mechanisms to restrict gene expression to specific cells or sites within solid tumours.
Specific DNA sequences, called hypoxia response elements (HREs), derived from
oxygen-regulated mammalian genes, have been incorporated into therapeutic DNA
constructs to ensure their expression only occurs in the low oxygen sites found in
tumours. Hypoxic conditions promote the binding of a family of transcription factors,
hypoxia-inducible factors (HIF) 1–3, to HREs, thereby promoting transcription.
However, HREs exhibit low levels of activity in the mild hypoxia found in some
normal tissue beds. We have therefore designed an ‘aerobic brake’ which could be
engineered into HIF-activated constructs to ensure activation only in severe hypoxia.
We propose to use a redox-responsive bacterial transcription factor (FLP; Fumarate-
Nitrate reduction Regulator protein (FNR) Like Protein) from Lactobacillus casei, as
such a brake. In this system, an FLP response element (FLP-RE) is introduced into a
promoter. FLP operates a simple redox switch based on the interconversion of dithiol
(inactive) and disulphide (active) forms, and is inactivated by virtual anoxia in E. coli.
We hypothesise that oxidised FLP would repress expression of the reporter in normoxia
or mild hypoxia by physically blocking the assembly and/or progress of the transcrip-
tion complex, and that this repression would be removed under anoxic conditions,
when FLP is converted to its reduced form. To assess the possible utility of FLP in gene
therapy, expression plasmids were constructed, placing flp under the control of the IE-
CMV promoter. Immunoblotting indicated that FLP was expressed in transiently trans-
fected HT1080 cells, but requires the fusion of a Nuclear Localisation Signal (from
EIA adenovirus protein) for efficient transport to the nucleus. The addition of several
amino acids to the N-terminus of FLP did not compromise its activity in bacteria and
the oxidised form of FLP is generated in mammalian cells. Furthermore, bandshift
assays showed that bacterial FLP binds to an FLP-RE cloned into a mammalian
promoter. Ongoing co-transfection studies with a reporter plasmid containing single or
multiple FLP-Res just downstream of the TATA box will test the ability of FLP to
repress gene expression in aerobic conditions. An alternative approach is to use FLP or
related factors to control gene expression in such bacteria as Salmonella, which have
been engineered to target and accumulate in solid tumours. We will show that the
endogenous FNR induces reporter gene expression under anoxia in Salmonella
typhimurium. Taken together, our data indicate that such bacteria-derived mechanisms
could possibly be used to target high-level expression of therapeutic genes (delivered
by viral, non-viral, cell-based, or bacterial vectors) to hypoxic/anoxic tumour regions.
2.7
THE SIGNIFICANCE OF MISMATCH REPAIR- AND P53
DEPENDENT APOPTOSIS IN THE SMALL INTESTINE, 
OJ Sansom*b, NJ Toftb, DJ Wintona, AR Clarke*, *=Dept of Biosciences,
University of Cardiff, a=Dept of Oncology, University of Cambridge, b=Dept of
Pathology, University of Edinburgh, UK
We and others have previously shown that Msh2 and p53 play a role in the initiation
of apoptosis following DNA damage. However the significance of this to long term
survival is still unclear. For example, after gamma irradiation, when there is clear p53
dependent apoptosis, p53 deficiency has not been reported to lead to increased clono-
genic survival or frequency of mutation in p53 null mice. We have now studied these
endpoints in relation to the mismatch repair gene Msh2. After treatment with the
methylating agents temozolomide and MNNG, we observe Msh2 dependent apoptosis
and, in the absence of Msh2, we see a significant increase in the mutation frequency as
scored at the Dlb1 locus. In stark contrast the methylating agent MNU does not elicit
MMR dependent apoptosis, but deficiency of Msh-2 does lead to increases in both
clonogenic survival and mutation frequency. We have also analysed the Msh2 depen-
dency of these responses with respect to cisplatin exposure, and find weak Msh-2
dependency in the apoptotic response but Msh2 dependency in either clonogenic
survival or mutation frequency. This latter result is of particular interest as Msh2 has
previously been reported to recognise the cisplatin adduct.
For all of the treatments listed above we find that the immediate apoptotic response
is p53 dependent, but we only observe a p53-dependent increase in clonogenic
survival following treatment with cisplatin.
In conclusion, we show that loss of Msh2 or p53 dependent apoptosis can lead to
both an increase in clonogenic survival and an increase in mutation frequency, prob-
ably as a consequence of the loss of the apoptotic pathway. However, despite the
attractiveness of the hypothesis that loss of apoptosis leads directly to increased
survival and thus higher levels of mutation, for many circumstances this is clearly not
the case.Oral Presentations 15
2.8
NOVEL RESPONSE OF THE P53 PATHWAY TO TAMOXIFEN IN
BREAST CANCER D Ziyaie*1, KL Ball1, TR Hupp2, A Ingram1, AM
Thompson1, 1Dept of Surgery & Molecular Oncology, 2Dept of Molecular &
Cellular Pathology, University of Dundee DD1 9SY, UK
The anti-oestrogen tamoxifen remains the first-line endocrine treatment of choice for
women in whom tumours are positive for oestrogen receptors. However, only a
proportion of these patients respond effectively to primary tamoxifen treatment. Some
50% of patients with oestrogen receptor positive tumours will respond to tamoxifen,
but many who initially respond to primary tamoxifen treatment will eventually relapse
and exhibit resistance to tamoxifen while on continuing treatment.
Although it is believed that anti-oestrogens such as tamoxifen exhibit both cyto-
static and cytotoxic properties, inducing cell cycle arrest and apoptosis respectively,
the exact mechanism by which tamoxifen inhibits tumour growth and molecular
changes that lead to tamoxifen resistance are not fully understood.
It is generally accepted that genetic mutation is fundamental to malignant transfor-
mation and in particular alterations of the p53 tumour suppressor gene are of clinical
significance. p53 abnormalities occur in nearly half of all human tumours including
breast cancer where mutation or over-expression of the protein is observed in up to
52% of cancers.
To investigate the relation of the anti-tumour properties of tamoxifen with p53 and
p21 (the p53-transactivated target gene mediating p53-dependent cell cycle arrest), we
have treated MCF-7, an oestrogen receptor positive wild-type (active) p53 and tamox-
ifen sensitive breast cancer cell line, with tamoxifen. Using western blot and FACS
analysis we have demonstrated that, in response to tamoxifen, these cells exhibit a
marked induction of p21 protein in the absence of p53 protein induction, corre-
sponding to an increase in the sub-G1 population of cells, accompanied by an increase
in G1 cell cycle arrest. p53 protein in tamoxifen treated cells, in contrast with MCF7
cells treated with adriamycin, was not phosphorylated at Ser392, a site whose modifi-
cation is a sensitive probe for p53 activation in the absence of changes in p53 protein
levels (ref).
These data suggest that p21 protein induction in response to tamoxifen is indepen-
dent of p53 protein activation. Current studies are centred on determining unambigu-
ously whether p21/p53 protein mediates, or is just responding to, the effect of
tamoxifen.
Jeremy P Blaydes and Ted R Hupp (1998) DNA damage triggers DRB-resistant
phosphorylation of human p53 at the CK2 site. Oncogene 17: 1045–1052
2.9
p53 MUTATIONS – AN EARLY EVENT IN AIDS-ASSOCIATED NON
HODGKIN’S LYMPHOMAS (NHL)? A Reddy*1, T Crook2, I Weller3
and DH Crawford1, 1Basic & Clinical Virology Group, University of Edinburgh,
EH9 1QH, 2LICR, London W2 1PG, 3University College London Hospital,
London WC1 6AU, UK
Chromosomal aberrations are a common feature of lymphomas associated with
Human immunodeficiency virus (HIV) infection. AIDS-NHL develops in around
5–10% of HIV-infected individuals and involves deregulation of proto-oncogenes
such as c-myc, bcl-2, bcl-6 and ras, as well as functional inactivation of tumour
suppressor genes, p53 and p16. Although the contribution of these genes to
lymphomagenesis has been well characterised, relatively little is known about pre-
lymphomatous molecular events that precede clinical presentation in these individ-
uals.
Persistent generalised lymphadenopathy (PGL) is an early manifestation of HIV
infection and is characterised by hyperplasia and progressive fragmentation of the B-
cell follicles, leading to end-stage lymphocyte depletion. We decided to analyse tissue
from 24 HIV-infected individuals with PGL for early defining genetic abnormalities.
The p53 gene is mutated in 50% of solid tumours and in 30–40% of AIDS-NHL.
Therefore, we investigated whether alterations in the gene occurred early in these
individuals. Mutations were detected in 3/24 (12.5%) PGL samples at codons 249
(G:T transversion), 238 (T:G transversion) and 229 (T:C transversion), by SSCP-PCR
and sequencing. In contrast, the gene was intact in 16 control reactive lymph nodes
and tonsils from HIV-uninfected individuals. This finding contradicts the popular
observation that p53 mutation is a late event, and suggests that in the context of HIV
infection structural lesions affecting the p53 gene are biologically important.
2.10
A NOVEL GERMLINE 7 BASE PAIR INSERTION IN P53; A
FUNCTIONAL STUDY OF THE RESULTING TRUNCATED
PROTEIN Jodie Rutherford*1, Carol E Chu2, Ruth S Charlton2, Paul
Chumas2, Graham R Taylor2, Xin Lu4, Diana Barnes3, Richard Camplejohn1,
1Richard Dimbleby Dept., St Thomas’ Hosp., SE1 7EH; 2St James’s
University Hosp., Leeds, LS9 7TF; 3ICRF Clin Oncol Unit, Guy’s Hosp., SE1
9RT; 4Ludwig Institute, St Mary’s Hosp., W2 1PG, UK
The p53 gene from a patient with a history of an osteogenic sarcoma and a choroid
plexus papilloma was sequenced for the presence of a germline mutation. A novel
heterozygous mutation was detected in exon five of p53 and was found to be a 7 base
pair insertion after nucleotide 13160 resulting in a frameshift producing a stop codon
at position 182. Various tests were carried out on this mutation in order to characterise
it in functional terms. The apoptotic assay (Camplejohn et al. Br J Cancer 72: 654,
1995) which measures the amount of apoptosis in lymphocytes before and after irra-
diation gave a normal result (46% apoptosis, which is well within the normal range of
30–60%). The FASAY (Flaman et al. PNAS 92: 3963, 1995), which is a yeast based
functional test for transactivation of targets by p53, also showed a wildtype result
when using mRNA from the patient (100% white colonies). The 7 base pair mutation
was synthesised by site-directed mutagenesis and was tested in the FASAY, this time a
mutant result (100% red colonies) was obtained. Failure of the FASAY to detect the
mutation using RNA from the patient’s own cells appears to be due to the absence or
very low level of mutant RNA in these cells. Transfection of this mutation into Saos-
2 cells, showed the production of a truncated protein (24 kD on 12% SDS PAGE),
which remained partially apoptotically active (70% wildtype). A similar report of
retention of apoptotic function by a truncated protein has been published (Haupt et al.
Genes & Develop 9: 2170, 1995). In the current study the mutated protein could not
transactivate target genes nor suppress the growth of Saos-2 colonies. However, the
truncated protein retained the ability to induce apoptosis in Saos-2 cells and the
patient’s apoptotic response was also normal. The possibility that apoptosis induction
occurs by p53 induced transrepression of target genes was tested using an SV40-based
target construct. However, the 7 base pair insertion mutant was non-functional in this
assay also. Thus the mechanism by which this mutant protein induces apoptosis
appears to be novel.
3.1
GASTRIC MALT LYMPHOMA: RESPONSE TO ANTI-
HELICOBACTER THERAPY IN THE ONGOING LY03
RANDOMISED CO-OPERATIVE TRIAL OF OBSERVATION VS
CHLORAMBUCIL AFTER ANTI-HELICOBACTER THERAPY E Zucca, E
Roggero, P Smith, C Traullé, C Copie-Bergmann, JC Delchier, R Souhami, F
Cavalli and B W Hancock*, For the IELSG, GELA and UKLG
Eradication of Helicobacter pylori infection has been reported to induce histological
regression in the majority of gastric MALT lymphomas. The International Extranodal
Lymphoma Study Group (IELSG), the Groupe d’Étude des Lymphomes de l’Adulte
(GELA) and the United Kingdom Lymphoma Group (UKLG) are conducting a coop-
erative trial (LY03) to ascertain for how long tumor regression is maintained, and
whether the addition of single-agent chlorambucil is of benefit in those patients who
respond to anti-helicobacter therapy.
From March 1995 to November 1999, 217 patients (39 from the UK) with
localised, histologically reviewed low grade MALT lymphoma of the stomach were
registered – 115 men and 102 women, with a median age of 68 years (range 20–85).
88% were positive for H. Pylori at diagnosis. Clinical presentations included
pain/dyspepsia (79%), anorexia (16%), nausea/vomiting (15%) and haemorrhage
(10%). The main sites of disease were antrum (55%), corpus (37%) and fundus (21%).
So far 189 patients have been evaluated for response to anti-helicobacter therapy;
histological regression of the gastric lymphoma was observed in 133 patients (70%,
95% C.I., 63% to 77%) with 105 (55%) complete and 28 (15%) partial remissions.
The median time to lymphoma regression was 7 months. It appears that anti-heli-
cobacter therapy can be safely given provided that a strict follow up is carried out. At
a median follow up of 26 months there have been 15 relapses of gastric lymphoma
(7%), most often with no evidence of H. Pylori reinfection. Histological transforma-
tion was observed only in 2 relapsed patients. Five patients have died so far, 1 of
progressive lymphoma after high grade transformation, 2 of solid cancers (lung and
melanoma) and 1 each of coronary thrombosis and pulmonary embolism. This study
is ongoing; so far 80 patients have been randomised on the chlorambucil vs. observa-
tion trial.16 Oral Presentations
3.2
OPTIMUM CONDITIONS FOR RADIOIMMUNOTHERAPY OF NON-
HODGKIN’S LYMPHOMA (NHL) USING CAMPATH-1H
MONOCLONAL ANTIBODY (MAB) P Hadjiyiannakis*1, G Hale2, R
Clutterbuck1, S Eccles1, P Carnochan1, C Lebozer1 VR McCready1, D
Catovsky1, A Horwich1, MJS Dyer1, 1: The Institute of Cancer Research and
2: The Therapeutic Antibody Centre, Oxford, UK
Background The unconjugated humanised IgG1 CD52 Mab, CAMPATH-1H is effec-
tive against B- and T-cell chronic leukaemias. It has reduced efficacy against
lymphomatous nodes, which may be treated with radioimmunotherapy. Tumour local-
isation of radiolabelled Mabs is improved by pre-treating patients with the unlabelled
Mab. The reasons for this improvement remained unclear. 
Aim To determine the criteria for optimum radioimmunotherapy of NHL. 
Methods CAMPATH-1H was radiolabelled with 111Indium (In) using DOT
Amaleimide as the chelating agent. The radiochemical purity was ³95% with
immunoreactivity ³80%. The radiolabelled Mab was stable in plasma. CD52+ve
human lymphoma xenograft models were raised subcutaneously in SCID/Nod mice.
The biodistribution of 8 mg 111In-CAMPATH-1H, either alone, or in the presence of
various other antibody constructs, was compared in these models. 
Results: Mean tumour uptakes (expressed as % injected activity/gram) at the 48
hour time point in the Wien133 B-cell model were: i) no pretreatment, 3.1 (SD 0.4); ii)
pretreatment with a non-Fc binding non-specific Mab 2.1(SD 0.4); iii) with unmodified
CAMPATH-1H 9.3 (SD 1.9); iv) with normal human immunoglobulin (hu-IG) 12.8(SD
1.5). The best therapeutic ratio was obtained by blockade with hu-IG (p<0.05 to <0.001
according to comparison). In a separate experiment, pretreatment with hu-IG was equiv-
alent to pretreatment with an Fc-binding non-specific Mab. Blockade with 500 mg of hu-
IG improved the biodistribution as compared to blockade with 44 or 200 mg (p<0.05).
Repeated doses of hu-IG (at –24 hours, 30 minutes, and + 48 hours) improved the ther-
apeutic ratios as compared to a single dose at –30 mins. Only the radiolabelled specific
antibody gave a favourable therapeutic ratio, with two radiolabelled non-specific anti-
bodies failing to do so. The time course data showed that tumour uptake exceeded blood
uptake at 36 hours and other normal tissue uptake at 16 hours. The maximal therapeutic
ratios were achieved after 48 hours and persisted beyond that time point. 
Discussion Blockade of Fc receptors markedly improved the tumour uptake and
therapeutic ratio of the radiolabelled Mab. Blockade with native Mab was less good,
presumably because of competition at the antigen binding site. Normal hu-IG is much
cheaper and more readily available than Fc-binding non-specific Mabs. The time
course for accumulation into lymphomatous masses suggest that for indium/yttrium a
two step targeting approach (e.g. with streptavidin/biotin) should be used to optimise
tumour delivery. Alternatively, a radioisotope with a longer half-life should be
employed. These strategies will be explored in patients with NHL.
3.3
BEXXAR™ (IODINE-131 TOSITUMOMAB) RADIO
IMMUNOTHERAPY FOR PATIENTS WITH B-CELL NON-
HODGKIN’S LYMPHOMA I Micallef, J Radford, K Britten, S Owen, D Deakin,
H Jan, R Foley, R Barlow, B Carrington, J Lawrance, S Vinnicombe, M
Harris, A Norton, A Lister, A Rohatiner, St Bartholomew’s Hospital, London
and Christie Hospital, Manchester, UK
Between July 1998 and November 1999, 40 patients (pts.), median age 53 years
(range 27–81 years) received Iodine-131 tositumomab therapy (Bexxar™, Coulter
Pharmacuetical Inc. and SmithKline Beecham) at two centres. 22 pts. were in a Phase
II study, 18 on a compassionate release basis. Treatment comprised a single dosi-
metric dose, followed by three whole body gamma counts obtained over 7 days, to
allow individualisation of the therapeutic dose. This was given 7–14 days after the
dosimetric dose. 33 pts. had follicular lymphoma (FL), 4 pts. mantle cell lymphoma
(MCL) and 3 pts. lymphoplasmacytoid lymphoma (LPC). In 7 pts., the disease had
transformed to diffuse large B-cell histology. All had received prior treatment (median
2, range 1–18); 6 had received Rituximab (anti-CD20) and 4 high-dose therapy (HDT)
supported by autologous haematopoietic progenitor cells. At the time of treatment, 18
pts. were in first progression, 10 in second, 10 in ³ third and 2 had refractory disease.
In 14 pts. the bone marrow was infiltrated at the time of treatment (<25%). Response
is currently evaluated at 33 pts., 7 have not yet reached the point of first evaluation.
The overall response rate (RR) at 7 weeks was 64% (21/33), complete remission (6),
partial remission (15) pts. The RR according to histological subtype was: FL 74%
(20/27), MCL 0 of 4, and LPC 1 of 2. Five of the 7 pts. with transformed disease are
evaluable, 2 responsed and 3 progressed. Three of 4 evaluable pts. who had previously
received Rituximab progressed. Three of 4 evaluable pts. who had previously
received Rituximab received HDT are evaluable; 2/3 responded. The principal toxi-
city was haematological: platelets ≤20 ´ 109/1: 15%, neutrophils ≤0.5 ´ 109/1: 20%,
Hb ≤10 g/dl: 30%. The nadir typically occurred at week 5–6; blood counts recovered
by week 8–9. No patients developed HAMA following treatment. At a median follow-
up of 6 months (1.5–15 months), 5/21 pts. have progressed. These results demonstrate
that Bexxar™ radioimmunotherapy is a safe and effective treatment for patients with
recurrent B-cell non-Hodgkin’s lymphoma.
This study was supported by the ICRF, CRC and both NHS Trust.
3.4
M-FISH ANALYSIS AND DETECTION OF CHROMOSOME
ABNORMALITIES PRE-TRANSPLANTATION IN PATIENTS
DEVELOPING THERAPY-RELATED MDS AND SECONDARY AML
FOLLOWING HIGH DOSE TREATMENT FOR NON HODGKINS
LYMPHOMA DM Lillington*, INM Micallef, E Carpenter, MJ Neat, JAL Amess,
J Matthews, NJ Foot, AZS Rohatiner, BD Young, TA Lister, ICRF Department
of Medical Oncology and Department of Haematology, St. Bartholomew’s
Hospital, London ECIM 6BQ, UK
Therapy-related myelodysplasia (tMDS) and secondary acute myeloid leukemia
(sAML) represent significant late complications in the treatment of primary malignan-
cies. In patients with non-Hodgkins lymphoma (NHL), the incidence of tMDS/sAML
following high-dose therapy (HDT) is between 5 and 15%. Twenty-eight of 230
patients with NHL who received cyclophosphamide and total body irradiation
supported by autologous haematopoietic progenitor cells at St. Bartholomew’s
Hospital have developed tMDS/sAML. The majority showed complex karyotypes
with complete or partial loss of chromosomes 5 and/or 7. Multi-colour fluorescence
in-situ hybridisation (M-FISH) was used to characterise complex rearrangements and
revealed cryptic changes not identified on routine G-banded analysis. To address
whether pre-transplant or transplant related factors play the critical role in the devel-
opment of tMDS/sAML, FISH analysis was undertaken to look for abnormalities
consistent with tMDS/sAML in cryopreserved bone marrow samples taken before
transplant. Significant levels of abnormal cells were found before HDT in 19 of 20
patients screened and who subsequently developed tMDS/sAML. Prior cytotoxic
therapy, therefore, plays an important aetiologic role and may predispose to the devel-
opment of tMDS/sAML. Using a triple FISH assay these ‘at risk’ patients can be iden-
tified before proceeding to HDT. This could have major implications for the
management of such patients.
3.5
REPAIR OF DNA INTERSTRAND CROSSLINKS AS A
MECHANISM OF CLINICAL RESISTANCE TO MELPHALAN IN
MULTIPLE MYELOMA VJ Spanswick*1, C Craddock2, M Sekhar3 and JA
Hartley1, 1CRC Drug-DNA Interactions Research Group, Dept of Oncology,
University College London and Royal Free Medical School, 91 Riding House
Street, London WIP 8BT, 2The Cancer Centre, Queen Elizabeth Hospital,
Edgbaston, Birmingham B15 2TH, 3Dept of Clinical Haematology, West
Middlesex University Hospital NSH Trust, Isleworth TW7 6AE, UK
High dose melphalan therapy followed by autologous peripheral blood stem cell
(PBSC) transplantation is considered to be an effective treatment regime for relapsed
multiple myeloma. However, despite its success nearly all patients relapse and
become refractory to further melphalan treatment. The basis of this clinical drug resis-
tance is unclear. Mechanisms of resistance to melphalan studied in vitro include alter-
ations in drug transport, detoxification and inhibition of drug-induced apoptosis. An
additional important mechanism is enhanced repair of drug-induced damage which
may result in resistance to nitrogen mustard based therapies in some haematological
malignancies such as chronic lymphocytic leukaemia.
The single cell gel electrophoresis (Comet) assay was used to assess the formation
and repair of melphalan-induced DNA interstrand crosslinks (ICL), the critical lesion
associated with melphalan cytotoxicity. Isolated plasma cells from bone marrow of
multiple myeloma patients were treated ex vivo with melphalan (0–100 mM) for 1 hr
followed by 16 hr drug-free post incubation to allow maximum formation of ICL.
Repair of ICL was assessed a further 24 hr later. Initially two patient populations were
studied; those who were melphalan naïve and those known to be clinically melphalan
resistant. ICL formation was found to be similar in both patient populations
suggesting that cellular uptake and detoxification mechanisms may not have a role in
the development of clinical resistance. Patients previously untreated with melphalan
demonstrated no evidence of ICL repair. In contrast, in a resistant patient who had
previously failed an autologous PBSC transplant following melphalan therapy, all ICL
were repaired within 24 hr. This evidence suggests that enhanced repair of melphalan-
induced ICL may be the major mechanism for development of clinical resistance.
Using the Comet assay it may be possible to detect the emergence of a resistance
phenotype, measure heterogeneity of response within the patient populations, and ulti-
mately predict the outcome of melphalan therapy in multiple myeloma.Oral Presentations 17
3.6
DEMONSTRATION OF FUNCTIONAL DNA MISMATCH REPAIR IN
LYMPHOBLASTS FROM PATIENTS WITH LEUKAEMIA EC
Matheson*1, AG Hall1, G Marra2, 1Molecular Pharmacology Laboratory,
Cancer Research Unit, Medical School, Framlington Place, Newcastle upon
Tyne, NE2 4HH, UK, 2Institute for Medical Radiobiology, August Forel-
Strasse 7, 8008 Zurich, Switzerland
DNA mismatch repair (MMR) plays an important role in maintaining the integrity of
the genome by repairing base-base mispairs and insertion/deletion loops that may
arise during normal DNA replication. Defects in the MMR system result in a mutator
phenotype and a susceptibility to cancer. In addition, MMR defects have recently been
identified as a cause of drug resistance. As current treatment protocols for leukaemia
commonly involve the use of etoposide, doxorubicin and thiopurine drugs, all of
which have been shown to be tolerated by cells which are defective in MMR, we have
analysed the protein expression of the main components of this pathway in a range of
leukaemias by immunoblotting and determined the functionality of the protein using a
mismatch repair assay.
A total of 12 lymphoblast samples from patients with acute lymphoblastic
leukaemia (ALL), acute myeloid leukaemia (AML) and chronic myeloid leukaemia
(CML) were analysed for expression of key mismatch repair proteins, hMLH1,
hPMS2, hMSH2, hMSH6 and PCNA by western blotting. All samples were compa-
rable in terms of blast % (all >90%) and proliferative activity. Cytoplasmic extracts
were also freshly prepared from each of the samples and the efficiency of these
extracts to repair DNA mismatches was tested using M 13mp2 heteroduplex substrate
containing a G.T mispair using an assay for in vitro MMR (Thomas, D.C., Umar, A.,
Kunkel, T.A. 1995. A Companion to Methods in Enzymology, Vol. 7, 187–197).
hMLH1, hPMS2 and hMSH2 proteins were highly expressed in all of the
leukaemic samples studied, however there was a wide variation in repair efficiency,
ranging from less than 1% in the case of a relapse ALL, to greater than 90% in the
case of a presentation ALL. There was no trend or correlation found with disease
state, although as this is a prospective study, the analyses will be ongoing.
Complementation studies using recombinant MutSa (hMSH2/hMSH6) and MutLa
(hMLH1/hPMS2) protein and cytoplasmic extract from known mismatch repair defi-
cient cell lines are currently being carried out on the samples.
To the best of our knowledge, this is the first time a mismatch repair assay has been
carried out on primary human tumour samples. The results suggest that assessment by
western blotting alone may be insufficient to determine mismatch repair status, at
least in human leukaemias.
3.7
TIMING AND DOSE CHEMOTHERAPY ARE CRITICAL TO
SUCCESSFUL OUTCOME WITH RADIOTHERAPY IN B-CELL
LYMPHOMAS J Honeychurch, AM Vandersteen, PWM Johnson, MJ Glennie,
TM Illidge, CRC Department of Oncology, Cancer Sciences Division,
Southampton General Hospital, Southampton University, SO16 6YD, UK
Radioimmunotherapy (RIT) has emerged as a highly promising new treatment for B-
cell lymphomas and is now expected to play an important part in the management of
these disease. However, a number of ongoing uncertainties remain, which include the
most appropriate way to integrate this new treatment into current protocols. We have
developed two in vivo models of B cell lymphomas and have specifically used them to
investigate the importance of the timing of administering the alkylating agent
Cyclophosphamide (CYC) before and after RIT.
Using A31 (CBA mice) and BCL1 (BALB/c) models, animals were injected with
106 cells and either given CYC on day 7 followed by RIT on day 14 or RIT on day 7
followed by CYC on day 14 and compared with the effects of RIT or CYC alone. The
RIT given included a panel of 131I labelled antibodies (anti-Id [Immunoglobulin idio-
type]; anti-MHC Class II, anti-CD40) previously reported as showing high therapeutic
efficacy in the BCL1 model (Illidge et al BLOOD 94:233–243). When given prior to
RIT, higher doses of CYC (5 mg) ameliorated the therapeutic effects of RIT with anti-
Id and anti-CD40 mAbs and survival was found to be similar to CYC alone. In
contrast animals treated with lower doses (1–3 mg) of CYC after RIT in the BCL1
model were long-term (>200 days) disease free survivors. The kinetics of CYC
induced peripheral T and B cells depletion was investigated in vivo in both BALB/c
and CBA mice and found to be dose dependent and to reach a nadir around day 7
when the RIT was administered. We believe that these depletion studies may explain
the decreased efficacy of CYC prior to RIT and underlie the critical role that immune
effector cells play in effective RIT. We conclude that the timing and use of immuno-
suppressive chemotherapy prior to RIT in B cell lymphomas may seriously affect the
successful outcome of durable disease free survival and that these findings have
important implications for implementing treatment strategies with RIT in the clinic.
3.8
DEXRAZOXANE PREVENTS THE EMERGENCE OF MULTIDRUG
RESISTANCE IN THE HUMAN LEUKAEMIA LINE, K562
J Sargent*1, C Williamson1, C Taylor1 and K Hellmann2, 1Haematology
Research, Pembury Hospital, Kent TN2 4QJ, 2Windleshaw House,
Withyham, Sussex TN7 4DB, UK
Dexrazoxane combined with doxorubicin (+ 5-fluorouracil+cyclophosphamide – the
FAC regime) leads to a significant decrease in doxorubicin cardiotoxicity and a signif-
icant increase in median survival time for patients with advanced breast cancer
responsive to FAC. The reason for this increase in survival may be related to a reduc-
tion in the emergence of multidrug resistance (MDR). In order to test this hypothesis,
we induced resistance to doxorubicin in the K562 cell line by growing cells in
increasing concentrations of doxorubicin (10–40 nM) in the presence (20 and 200
nM) and absence of dexrazoxane. The doxorubicin sensitivity of all resultant sublines
was measured using the MTT assay. Flow cytometry was used to assess the MDR
phenotype, measuring P-glycoprotein expression with MRK 16 plus indirect immuno-
fluorescence and drug accumulation in the presence and absence of PSC 833 for func-
tional P-glycoprotein. Long-term growth in doxorubicin increased the cellular
resistance (IC50) of K562 cells in a concentration dependent manner (r2=0.999). This
increase in IC50 was markedly impaired in the presence of dexrazoxane (p<0.001). In
parallel, both the induction of P-glycoprotein expression and its function were signif-
icantly reduced in the presence of dexrazoxane (p<0.0001).
K562dox30 K562dox30
+DXRz (20 nM)
DOX IC50 (mM) 8.6 0.58
Pgp (ratio: fluorescence test/control) 16.5 2.05
Drug accumulation 17.2 1.07
(ratio: fluorescence +PSC/–PSC)
These results suggest that concomitant treatment of patients with initially drug-
sensitive disease with an agent such as dexrazoxane, might suppress the appearance of
resistant MDR subclones so allowing the responders to continue to respond.
3.9
A POPULATION-BASED STUDY OF INCIDENCE AND MORTALITY
FOR OSTEOSARCOMA IN ENGLAND AND WALES
PJ Jankowska*1, P Babb2, MJ Quinn2, JS Whelan1, 1Meyerstein Institute of
Oncology, Middlesex Hospital, London WC1E 6BA, 2Office for National
Statistics, 1 Drummond Gate, London SW1V 2QQ, UK
Background Accurate data about the epidemiology of rare cancers are not readily
available. This study describes for the first time the incidence of and survival from
osteosarcoma for England and Wales.
Methods Incidence data on 2931 histologically-confirmed osteosarcomas, as
collated by the Office for National Statistics (ONS) between 1971 and 1993, were
analysed by age, sex and site. Survival analyses (sub-classified by sex, deprivation
category, time cohort and NHS region) were performed on the data available for chil-
dren aged 0–15 and diagnosed before 1991.
Results The incidence of osteosarcoma in England and Wales was 4.1 per million
in 1993, compared with 5.7 in 1971. The rates were slightly higher for males than
females. A bimodal age distribution was confirmed 57% of cases arose in the lower
limb and 13% in the upper limb. The percentage distribution in the
pelvis/sacrum/coccyx, craniofacial bones, vertebral column (excluding sacrum and
coccyx) and ribs/sternum/clavicle is 11%, 5%, 3% and 3% respectively. 6% of
osteosarcomas had an unspecified site code. For children diagnosed in 1971–75 one-
year survival was 55% and five-year survival 17%. Those diagnosed between
1986–90 had one-year survival of 88% and five-year survival 51%. The average
increases in relative survival between successive five-year periods from 1971–75 to
1986–90 were 11% for one-year survival and 12% for five-year survival. There were
no survival differences between boys and girls. Survival increased substantially in
every NHS region. There were no statistically significant relations between survival
and socio-economic deprivation.
Conclusions The fall in the incidence of osteosarcoma is most likely due to
improved diagnosis, principally in older patients. The incidence data confirm previous
reports of regional data from Europe and the SEER data in the USA. Improved one-
year and five-year survival from osteosarcoma in children reflect more effective treat-
ment. Further analyses of these data will be carried out to determine if these
improvements of survival in osteosarcoma are maintained. Population-based data can
provide valuable information about rare cancers. Such data may be useful in guiding
future allocation of resources for health care provision and research but may be
limited by data quality.18 Oral Presentations
3.10
LONG-TERM SURVIVAL IN LOCALISED EXTREMITY
OSTEOSARCOMA: MATURE FOLLOW-UP FROM TWO
RANDOMISED TRIALS OF THE EUROPEAN OSTEOSARCOMA
INTERGROUP JS Whelan*1, S Weeden2, B Uscinska2 and A McTiernan1, On
behalf of the European Osteosarcoma Intergroup, 1London Bone and Soft
Tissue Tumour Service, Middlesex Hospital, UCLH Hospitals NHS Trust,
London WIN 8AA, 2Cancer Division, MRC Clinical Trials Unit, 222 Euston
Road, London W1N 2DA, UK
The European Osteosarcoma Intergroup (EOI) has completed two large randomised
trials in localised extremity osteosarcoma. EOI BO02/80831 was open to accrual
between 1983 and 1986, 179 eligible patients were randomised between two-drug
(cisplatin and doxorubicin) and three-drug (cisplatin, doxorubicin and methotrexate)
therapy. Between 1986 and 1993, 391 eligible patients were randomised into EOI
BO03/80861 which compared the same two-drug regimen with prolonged multidrug
therapy based on the T10 regimen.
Mature follow-up data is now available for these 570 patients. The median follow-
up time is 9.6 years, 94% of patients have been followed to death or 5 years. 288
(51%) patients received two-drug therapy, 90 (16%) received three-drug and 192
(34%) multi-drug. The median age of patients was 16 (range 3–40) and 363 (64%)
were male. Primary tumour site was femur in 315 (55%), tibia or fibula in 177 (31%)
and upper limb in 78 (14%).
Limb salvage surgery was possible for 373 (65%) patients. Good histological
response based on > 90% necrosis occurred in 30% of patients. Overall 5-year
survival was 56% (95% CI 52–60%) and 5-year progression-free survival was 44%
(95% CI 40–48%). There were no significant differences in survival based on trial,
treatment, age or sex. Good histological response, tumours of the tibia or fibula and
limb-conserving surgery were all associated with improved survival.
Site of first recurrence was local in 21 (4%), bone in 20 (4%), lung in 189 (33%)
and combined for 58 (10%) patients. First recurrences after 5 years are uncommon –
only 3 occurred in this patient group. Two patients died from chemotherapy-related
toxicity more than 5 years after randomisation.
These data, collected prospectively for a large group of patients, provide important
information on long-term survival for primary extremity osteosarcoma.
4.1
PREOPERATIVE CHEMORADIOTHERAPY IN CANCER OF THE
OESOPHAGUS: EVIDENCE OF RADIATION AND
CHEMOTHERAPY DOSE RESPONSE JI Geh*1, SJ Bond2, SM Bentzen3, R
Glynne-Jones2, 1Queen Elizabeth Hospital, Birmingham; 2Mount Vernon
Hospital and 3Gray Laboratory, Northwood, UK
Introduction Patients achieving pathological complete response (pCR) following
preoperative chemoradiotherapy (CRT) for oesophageal cancer have improved
survival. We identified 52 trials (46 phase II: 6 randomised) of preoperative CRT
totalling 3078 patients; pCR was observed in 23%. Different radiotherapy doses &
fractionations and chemotherapy drugs, doses & scheduling were prescribed in each
trial which may account for the large differences in pCR rates achieved. The aim of
this meta-analysis was see if a dose response relationship exists between radiotherapy
& chemotherapy dose and pCR.
Methods Trials were included within this meta-analysis if they used a single radio-
therapy dose/fractionation, used a single 5FU, cisplatin or mitomycin C based
chemotherapy regimen and provided information on patient numbers, age, resection
& pCR rates. Twenty six trials were eligible (1335 patients) of which 311 patients
(24%) achieved pCR. The endpoint used was pCR and the following covariates were
analysed; radiotherapy dose, radiotherapy dose 3 dose/fraction, radiotherapy treat-
ment time, chemotherapy dose, median age of patients within trial. Multivariate
logistic regression was used to predict the probability of pCR following preoperative
CRT.
Results Increasing radiotherapy dose was associated with increasing pCR rates
(p=0.006). The alpha/beta ratio of oesophageal cancer was estimated to be 4.91 Gy
(95% CI 1.48–16.68 Gy). Increasing radiotherapy treatment time reduced the proba-
bility of pCR (p=0.035); estimated radiotherapy dose lost per day was 0.83 Gy (95%
CI 0.25–1.39 Gy). There was also evidence of a chemotherapy dose response relation-
ship for both 5FU (p=0.003) and cisplatin (p=0.018); 1 gram/m2 of 5FU estimated to
be equivalent to 2.60 Gy (95% CI 1.10–7.21 Gy) and 100 mg/m2 of cisplatin esti-
mated to be equivalent to 11.1 Gy (95% CI 3.00–39.0 Gy). Mitomycin C dose did not
seem to influence pCR rates (p=0.60). The lower the median age of patients within the
trial, the higher the tendency to achieve pCR (p=0.019).
Conclusions There was significant evidence of a dose response relationship
between increasing radiotherapy, 5FU and cisplatin dose and pCR. Additional signifi-
cant factors were radiotherapy treatment time and median age of patients within the
trial.
4.2
A PHASE II STUDY OF GEMCITABINE AND FLUTAMIDE IN
ADVANCED PANCREATIC CANCER A Mayer*1, J Shaw1, SD ‘Ath1,
P Price2, C Blesing3, P Corrie1, 1Oncology Centre, Addenbrooke’s NHS Trust,
Cambridge, 2Dept of Oncology, Hammersmith Hospital, London, 3Dept of
Oncology, The Churchill, Oxford Radcliffe Hospital, Oxford, UK
Patients with pancreatic cancer frequently present with advanced disease and life
expectancy is measured between 3 and 9 months. Survival benefit of chemotherapy
has so far been limited. Both, Gemcitabine (Burris et al., 1997), a deoxycitidine
analogue and Flutamide, an antiandrogen (Greenway, 1998) have been reported to
improve median survival. We report the first study combining Flutamide and
Gemcitabine in pancreatic cancer.
Patients with histologically proven non-resectable pancreatic cancer and measure-
able disease received Gemcitabine (1 g/m2) on day 1, 8 and 15 of a 28 day cycle, while
Flutamide 250 mg tds was given concurrently over the whole period. Tumour imaging
was performed prior to entry into the study and subsequently after every two cycles.
So far, 15 patients (11 male, 4 female, median age 58, range 36–72 years) have
been entered into the study. Performance status was 0, 1, and 2 in 6, 5, and 4 patients
and tumour stage was II, III and IV in 3, 3, and 8 patients, respectively. The remaining
patient was suffering from local recurrence after pancreatectomy. A median of 3
cycles of Gemcitabine was given (range 1–10). The best response was a partial
response (PR) after 2 cycles in 2 and after 4 cycles in another 2 patients (response rate
27%). A minor response (MR) occurred in 1 patient after 5 cycles. Four patients
showed stable disease (SD), 4 patients progressive disease (PD), 2 patients are
currently awaiting their first reassessment CT scan. Median survival has not been
reached yet. The full dose of Gemcitabine was given in 9 patients, dose modifications
were necessary due to grade 3 neutropenia (1 patient), grade 3 anemia (1 patient),
grade 1 thrombopenia (3 patients), and grade 3 hypersensitivity (1 patient). Flutamide
was stopped due to grade 3 liver toxicity in 1 patient and due to grade 2
nausea/vomiting in a second patient. It was reduced to 250 mg bd in 2 patients due to
grade 2 hot flushes in 1 patient and grade 2 nausea/vomiting in another patient.
Further grade 3 toxicity included nausea/vomiting in 2 patients, while the majority of
patients experienced only mild toxicity (grade 1/2 fatigue in 5 patients, grade 1/2
nausea/vomiting in 3 patients).
The response rate of 27% indicates that Gemcitabine in combination with
Flutamide is a promising regimen in advanced pancreatic cancer with acceptable toxi-
city.
Greenway (1998), Br Med J 316: 1935
Burris (1997), J Clin Onc 15: 2403
4.3
A PHASE I TRIAL OF ANTIBODY DIRECTED ENZYME PRODRUG
THERAPY (ADEPT) IN PATIENTS WITH ADVANCED
COLORECTAL CARCINOMA OR OTHER CEA PRODUCING TUMOURS RJ
Francis*1, SK Sharma1, L Sena, C Springer2, AJ Green1, LD Hope-Stone1, J
Martin2, KL Adamson1, D O’Malley1, E Tsiompanou1, H Shahbakhti1, S
Webley1, D Hochhauser1, AJ Hilson1, RHJ Begent1, 1Department Oncology,
Royal Free and UCL Medical School, London NW3 2PF, 2CRC Centre for
Cancer Therapeutics, Inst. of Cancer Research, Surrey SM2 5NG, UK
Colorectal cancer is the second leading cause of cancer death in the UK. Conventional
treatments remain unable to cure patients with advanced or metastatic disease, so
there remains an urgent need to develop novel therapies.
In antibody-directed enzyme prodrug therapy (ADEPT) a prodrug is activated
selectively at the tumour site by an enzyme targeted to the tumour by an antibody
(antibody – enzyme conjugate). Previous clinical trials have shown evidence of
tumour response1,2. However, effectiveness was limited by the long half-life of the
activated drug, which diffused back into the circulation and caused myelosuppression.
Also, the targeting system, although giving high tumour to blood ratios of antibody-
enzyme conjugate (10,000:1) was excessively complicated, requiring administration
of a clearing antibody in addition to the antibody-enzyme conjugate. The purpose of
this study was to study tumour targeting of the antibody-enzyme conjugate without
the clearing antibody, and to investigate a new highly potent prodrug (bis-iodo phenol
mustard, ZD2767P) whose activated form has a short half-life.
Between Nov 1997 – Nov 1999 28 patients were recruited and 27 treated in the
phase I ADEPT trial. The MTD of ZD2767P was reached at 15.5 mg/m2 ´ 3 with a
serum carboxypeptidase G2 (CPG2) level of 0.05 U/mL. Thrombocytopenia and
neutropenia limited dose escalation. Other toxicities were mild. Without a clearing
antibody this system achieved tumour: normal tissue ratios of antibody-enzyme
conjugate of less than 10:1 (tumour biopsy and gamma camera) at the time of prodrug
administration. The ZD2767P prodrug was shown to clear rapidly from the circula-
tion, activated drug was not measurable in the blood, and evidence of drug effect was
demonstrated by the presence DNA interstrand crosslinks in a tumour biopsy (comet
assay).
Conclusion: The A5B7–CPG2 chemical conjugate requires a clearing antibody to
achieve high tumour to normal tissue ratios that are required for therapy. However a
genetic fusion protein of antibody – enzyme may solve this problem. ZD2767P
prodrug was activated in vivo by CPG2 and has potential for use in ADEPT systems in
which higher tumour to normal tissue enzyme ratios are achieved.
This work was done on behalf of the CRC Phase I/II Committee.
1 Bagshawe K et al (1995) Tumour Targeting 1: 17–30
2 Napier M et al (2000) Clin Cancer Res (in press)Oral Presentations 19
4.4
PHASE II STUDY OF IRINOTECAN AND HIGH DOSE INFUSIONAL
5-FU AND FOLINIC ACID (MODIFIED DE GRAMONT) FOR FIRST-
LINE TREATMENT OF ADVANCED OR METASTATIC COLORECTAL
CANCER P Leonard,*1 JA Ledermann,1 R James,2 D Hochhauser,1 M
Seymour3, 1Royal Free and University College Medical School, London,
2Christie Hospital Manchester, 3Cookridge Hospital Leeds, UK
Aims To investigate the response and toxicity of the combination of irinotecan with a
modified de Gramont schedule of infusional 5-fluorouracil (5-FU) and folinic acid as
first line therapy in advanced or metastatic colorectal cancer. 
Methods Forty-two patients (16 F, 26 M) with a median age of 57 y (range 34–79
y) and WHO performance status 0–1 were treated. None had previously received
chemotherapy except in the adjuvant setting. Every two weeks, patients received the
following regimen: (a) irinotecan 180 mg/m2 over 30 mins by iv infusion, (b) L-
folinic acid 175 mg (or d, L folinic acid 350 mg) over 2 hrs by iv infusion (c) bolus iv
injection of 5-FU 400 mg/m2 followed by 5-FU 2400 mg/m2 over 46 hrs by iv infu-
sion. Three patients had 5-FU at the infusional dose of 2800 mg/m2, but following two
toxic deaths the dose was reduced to 2400 mg/m2. 
Results The median number of treatment cycles administered was 8 (range 1–12)
with 31 patients completing at least 6 cycles and 16 patients completing 12 cycles.
Dose reductions of both drugs were required in 10/42 (24%) patients because of side
effects. In total 38/42 (90%) were evaluable for response. Of these, 11/38 (29%)
patients had a partial response and a further 13/38 (34%) achieved disease stabilisa-
tion. Median survival times have not yet been established as the vast majority of
patients are still alive. Haematological toxicity grade (Gd) 3/4 occurred in 7 (16%)
patients, including two patients who died at the start of the study. Thrombocytopenia
was not seen. Non-haematological toxicities included: diarrhoea Gd1/2 (28%), Gd3/4
(5%); nausea and vomiting Gd1/2 (23%); mucositis Gd1/2 (21%); alopecia Gd1/2
(33%); no patients reported Gd3/4 alopecia; dizziness and disorientation was experi-
enced in two patients. Three patients were given atropine for cholinergic side effects. 
Conclusion These data show that the modified de Gramont schedule in combina-
tion with irinotecan offers an active and well tolerated first line treatment for
advanced or metastatic colorectal cancer. The overall toxicity was predictable,
reversible and manageable, the main dose limiting toxicity was neutropenia. This
regimen will now be used in a randomised study conducted by the Medical Research
Council.
4.5
INDIVIDUALIZING TREATMENT APPROACHES WITH
ANTIFOLATE ANTIMETABOLITES 1AL Jackman, 1HER Ford, 1D
Cunningham, 1DC Farrugia, 1F Mitchell, 2K Danenberg and 2P Danenberg,
1CRC Centre for Cancer Therapeutics, The Institute of Cancer Research,
and the Royal Marsden Hospital Trust, Sutton, Surrey; 2University of
California, Los Angeles, USA
The specific antifolate thymidylate synthase (TS) inhibitor raltitrexed (RTX; Tomudex™)
gives similar response rates to 5-fluorouracil (5-FU) and leucovorin or continuous infusion
5-FU in colorectal cancer. Preclinical studies suggest that RTX and 5-FU should have
incompletely overlapping spectra of antitumour activity. This is also predicted from their
different mechanisms of cellular uptake, metabolism and specificity for the target, TS.
Although the toxicity profile of RTX is generally more acceptable than 5-FU/LV, a small
percentage of patients treated with RTX develop a life-threatening combination of diar-
rhoea and neutropenia. Elevated levels of TS, thymidine phosphorylase (TP) and dihy-
dropyrimidine dehydrogenase (DPD) are associated with non-response to 5-FU. Taken
together, this information suggests a role for individualised therapy in colorectal cancer
based on gene expression patterns or pharmacodynamic end-points. 29 patients were
treated with RTX 3 mg/m2 3-weekly, and 24 underwent pretreatment (day –1) and post-
treatment (day 5) biopsies of metastatic tumour (liver) and normal gastrointestinal mucosa.
Pre-treatment biopsies were analysed for TS, folylpolyglutamate synthetase (FPGS), TP
and DPD mRNA by RT-PCR. Pre- and post-treatment biopsies were stained for TS, Ki-67
(a proliferation marker) and dUTPase by immunohistochemistry. Plasma and tissues
samples were assayed for RTX levels by radioimmunoassay, and plasma for 2¢deoxyuri-
dine (dUrd; a surrogate marker of TS inhibition) by HPLC. Most patients are now evalu-
able for response. Results have shown that low TS/b-actin mRNA (≤ 4.1 ´103; previously
defined cut-off for response to 5-FU) was significantly associated with response (5/6
responders compared to 1/11 non-responders; p=0.005). By contrast, high gut TS expres-
sion was associated with anti-proliferative toxicity. 6/9 patients with gut TS/b-actin ³5.9 ´
103 experienced grade 2–4 toxicity compared with 0/9 with gut TS/b-actin <5.9 ´ 103
(p=0.009). 3/6 responding patients had very high levels of TP compared to 2/11 non-
responders, suggesting than unlike 5-FU/LV high tumour TP may be a positive factor for
response to RTX. A response was seen in one patient with high DPD. Tumour RTX
(polyglutamate) levels were ~28-fold higher than plasma, and were higher in the mucosa
of patients experiencing gastrointestinal toxicity (0.15±0.06 ng/mg tissue compared to
0.09±0.06 ng/mg in patients without toxic effects; p=0.09). Plasma dUrd was elevated
within 24 h, returned to pretreatment by day 5 in most cases and did not correlate with
response or toxicity. These data suggest that individualised therapy, based on gene expres-
sion patterns, may be valuable in the treatment of advanced colorectal cancer. In addition,
cytotoxicity from RTX may have an underlying molecular cause, and patients at risk could
be predicted with reasonable accuracy by pretreatment biopsy.
4.6
DIFFERENTIAL EXPRESSION OF DIHYDROPYRIMIDINE
DEHYDROGENASE AND THYMIDINE PHOSPHORYLASE IN
COLORECTAL TUMOURS AND PRIMARY METASTASES ESR Collie-
Duguid*, SJ Johnston, LM Boyce, J Cassidy and HL McLeod, Dept of
Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZD,
UK
Current therapies for colorectal cancer are clearly inadequate as 450 000 people still
succumb to the disease each year. Although the aetiology of colorectal cancer is
extremely complex, a key feature of the malignant phenotype is uncontrolled cell
growth and proliferation. It is essential for actively proliferating cancer cells to
increase their rate of DNA synthesis in order to progress through the cell cycle.
Increased pyrimidine usage is a common feature in tumour tissues. Thymidine phos-
phorylase (TP) is the initial enzyme in the salvage pathway of pyrimidine synthesis,
thereby regulating levels of pyrimidine nucleosides available for DNA synthesis.
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate limiting enzyme of
pyrimidine catabolism and results in the degradation of pyrimidine bases, thereby
influencing levels of uracil and thymine available for DNA synthesis. Levels of TP
and DPD are correlated with the clinical efficacy of pyrimidine anti-metabolites
commonly used in the treatment of colorectal cancer. DPD and TP protein levels were
measured by Western blotting in primary colorectal carcinomas (n=15), colorectal
liver metastases (n=4) and adjacent normal tissues in order to investigate possible
differential regulation of these enzymes in colorectal tumours. DPD was reduced in
67% (10/15) of colorectal tumours (mean tumour/normal=0.52, n=10) and in all liver
metastases (mean tumour/normal=0.53, n=4) compared to the corresponding normal
tissue. In contrast, TP was increased in 80% (12/15) of colorectal tumours (mean
tumour/normal=18.91, n=12) and in all metastases (mean tumour/normal=2.61, n=4).
TP and DPD protein expression were highly variable in normal (mucosa 474-fold and
45-fold, respectively; liver 4-fold and 2-fold, respectively) and tumour (primary 34-
fold and 6-fold, respectively; metastases 2-fold and 3-fold; respectively) tissues. The
ratio of TP:DPD was higher in 87% of colorectal tumours and in all liver metastases
compared to the adjacent normal tissues. The majority of primary and all secondary
colorectal tumours demonstrate co-ordinated down-regulation of DPD and up-regula-
tion of TP protein. This may represent a mechanism whereby the tumour optimises
conditions for growth by increasing levels of pyrimidine nucleotides available for
DNA synthesis. Further insight into the factors controlling pyrimidine levels in
neoplastic tissues will provide novel molecular targets to inhibit DNA synthesis and
allow either modulation of existing therapies or development of novel, more effective
agents.
4.7
CD44V3,8–10 IN PROGRESSION OF COLORECTAL CANCER,
AND SERUM LEVELS AS A MEASURE OF TUMOUR
EXPRESSION MG Tutton*1,2, M George1,2, S Eccles2, I Swift1, AM Abulafr1,
1Colorectal Dept, Mayday University Hospital, Surrey, 2Institute of Cancer
Research, Sutton, Surrey, UK
Introduction CD44 is an adhesion molecule expressed on epithelial cells with
multiple variants derived by alternative splicing. In colorectal cancer, variant 6 has
been associated with tumour progression. A newly described variant, CD44v3,8–10,
localises with gelatinase B (MMP-9; a key enzyme in invasion and angiogenesis) in
breast carcinoma cell invadopodia. We studied colorectal cancers to determine: 1)
expression of CD44v3,8–10 in relation to disease progression and 2) whether shed
CD44, detectable in sera, reflects expression levels in resected surgical specimens.
Methods mRNA was extracted from 13 adenomatous polyps, 50 primary
colorectal cancers and paired normal colonic specimens. Using specific primers for
CD44std, CD44v3, and CD44v6, RT-PCR products were semi-quantified and corre-
lated both with stage and with preoperative sera levels of the total soluble CD44 by
enzyme-linked immunosorbent assay. Band sizes were used to identify specific splice
variants.
Results CD44v3,8–10 was expressed both within normal colonic tissue and also
colorectal cancers with a significant increase both within adenomatous polyps and
cancers. This suggests that increases in CD44v3,8–10 are an early event in colorectal
cancer, as has been described for variant 6 and confirmed in this study.
Splice variant Normal colon Polyps Cancers
Mean expression (relative to b-actin) +/– SE *p<0.05 vs normal
CD44std 0.30 +/– 0.09 0.08 +/– 0.03 0.30 +/– 0.04
CD44v6–10 0.98 +/– 0.24 1.30 +/– 0.17* 0.83 +/– 0.14
CD44v8–10 0.01 +/– 0.01 0.08 +/– 0.06 0.12 +/– 0.03*
CD44v3,8–10 0.46 +/– 0.12 1.41 +/– 0.23* 0.95 +/– 0.10*
Using CD44std primers the total tumour expression of CD44 was found to signifi-
cantly correlated with levels of total soluble CD44 in sera (p=0.015; Spearman’s
correlation). Individual variant analyses will follow where feasible.
Conclusion Increased expression of CD44v3,8–10 is an early event in colorectal
cancer. This molecule may be involved in tumour invasion via association with MMP-
9 and also, via its variant 3 exon (which is a low affinity receptor for growth factors
such as bFGF) may potentiate angiogenesis. Changes in tumour expression are also
reflected in sera and may be detected by simple serological assays.20 Oral Presentations
4.8
COMPARISON OF VASCULAR PERMEABILITY MEASURED BY
DYNAMIC MRI AND SERUM/PLASMA VEGF IN LOCALLY
ADVANCED RECTAL CANCER ML George1,3*, ASK Dzik-Jurasz2, A
Padhani2, MO Leach2, IJ Rowland2, SA Eccles3, RI Swift1, 1Dept of Surgery,
Mayday Hospital, 2Clinical Magnetic Resonance Research Group, Royal
Marsden Hospital, 3Section of Cancer Therapeutics, Institute of Cancer
Research, Sutton, UK
Aims Vascular permeability is increased by VEGF and can be assessed radiologically
with dynamic MRI. This study examines whether tumour vascular permeability,
assessed by paramagnetic contrast enhancement kinetic analysis, correlates with
systemic VEGF in locally advanced rectal cancer.
Methods 21 patients with locally advanced adenocarcinoma of the rectum, 5 with
liver metastasis, were assessed. All examinations were carried out on a 1.5T Siemens
Magnetom Vision system using a pelvic phase array coil. A 10 mm slice through the
main bulk of the tumour was defined after imaging the full extent of the tumour using
a T2 weighted turbo spin echo sequence. Double dose (0.2 mmol kg–1) Gd-DTPA was
administered at 5 mls–1 by power injector and data acquired post contrast for at least 4
minutes. Analysis was performed of line using Tofts model. Serum and plasma VEGF
samples were taken from the patients just prior to entering the magnet. VEGF levels
were determined by ELISA (R&D Systems, Abingdon, UK). 18 patients had plasma
and serum samples and 3 plasma only. Platelet counts were recorded and the VEGF
per platelet was calculated.
Results Median serum and plasma VEGF were 356.5 pgml–1 and 36.9 pgml–1
respectively. Whole tumour permeability correlated with serum VEGF (r = 0.47, p =
0.049) but not plasma VEGF levels (r = 0.32, p = 0.16). The VEGF/platelet correlated
with tumour vascular permeability (r = 0.53, p = 0.025) but absolute platelet count did
not (r = –0.1, p = 0.7). There was no difference in tumour permeability between those
with or without liver metastasis but the numbers are small.
Conclusion Only serum VEGF and VEGF/platelet correlated with vascular
permeability. The vascular permeability may be affected by VEGF release from
platelets within the tumour’s microenviroment, with MRI permeability reflecting
‘dynamic angiogenesis’.
4.9
‘IPM’: A NEW OUTPATIENT SCHEDULE OF IRINOTECAN,
CISPLATIN AND MITOMYCIN FOR THE TREATMENT OF SOLID
TUMOURS J Shamash*, S Slater, J Steele, M Tischkowitz, D Farrugia, P
Wilson, C Gallagher, T Oliver, R Rudd, M Slevin, Dept of Medical Oncology,
St Bartholomew’s Hospital, London ECIA 7BE, UK
Introduction The combination of cisplatin and irinotecan shows promise in a wide
range of tumors. The optimal schedule remains to be determined and the addition of a
third drug may improve efficacy. Mitomycin has proven activity in many solid tumors
and was added to make the combination ‘IPM’. Cisplatin 40 mg/m2 (days 1 and 15),
irinotecan 100 mg/m2 (days 1 and 15 [70 mg/m2 in patients (pts) previously treated
with chemotherapy]) and mitomycin C 6 mg/m2 (day 1 only) were administered in a
28-day cycle on an outpatient basis. Toxicity was assessed in five tumours: (1)
untreated, inoperable gastric and oesophageal cancer (17 pts, 12 evaluable for
response); (2) untreated pancreatic cancer (10 pts, 5 evaluable); (3) relapsed small-
cell lung cancer (SCLC) (13 pts, 7 evaluable); (4) cytokine-refractory metastatic renal
cell carcinoma (RCC) (15 pts, 14 evaluable); (5) relapsed malignant pleural mesothe-
lioma (7 pts, 4 evaluable).
Patient characteristics Median patient age was 54 years (range 35–75 yrs). All
pts had performance status 0–3. In the SCLC pts the median progression free interval
(PFI) after cisplatin/etoposide-based therapy was 14 months. Four had developed
brain metastases despite prophylactic cranial irradiation. The median PFI following
cytokine-based therapy in RCC pts was 4 months.
Toxicity and response A median of 4 cycles (range 1–6) were administered, of
which 143 are evaluable for toxicity. There was one treatment related death. Grade
3–4 toxicities: malaise: 14%; infection: 5%; diarrhoea: 2%; grade 2: alopecia 31%.
Objective response rates: (1) untreated gastro-oesophageal: PR 5 (42%), SD 4 (33%),
PD 3 (25%); (2) untreated pancreatic cancer. CR 1 (20%), PR 1 (20%), SD 2 (40%),
PD 1 (20%); (3) relapsed SCLC: PR 4 (57%) all of whom had brain metastases, SD 2
(29%), PD 1 (14%), median overall survival = 282 days (range 13–377); (4) refrac-
tory. RCC: PR 0 (0%), SD 8 (57%), PD 6 (43%), median progression-free survival =
5 months; (5) relapsed malignant pleural mesothelioma: PR 3 (75%), SD 0 (0%), PD
1 (25%).
Conclusions IPM is a novel regimen with activity in the 5 tumour types evaluated
and has the advantage of outpatient administration with acceptable toxicity.
4.10
INHIBITION OF GROWTH OF COLON TUMOUR CELLS BY
CURCUMIN CORRELATES WITH INHIBITION OF THE IkB
KINASE AND DOWN REGULATION OF CYCLIN D1 Simon Plummer1,
Debbie Wakelin1, Marianne Bouer1, Paul Shepherd1, Lynne Howells1,
Andreas Gescher1, Sek Chow2 and Margaret Manson1, MRC Toxicology Unit1
and Centre for Mechanisms of Human Toxicity2, University of Leicester,
Leicester LE1 9HN, UK
Curcumin, an antioxidant component of the spice turmeric derived from the rhizome
of Curcuma longa, possesses a wide range of effects which can be associated with
both chemopreventive and anti-cancer activity. We have recently shown that likely
targets of curcumin, which account partly for its ability to inhibit induction of the
cyclooxygenase-2 (COX-2) gene by colon tumour promoters, are the IkB kinases IKK
a and b. Whilst the induction of COX-2 gene expression by tumour promoters is
thought to be mediated via AP1 and NF-kB, it has been unclear whether these tran-
scription factors are involved in the constitutive overexpression of COX-2 seen in
colon tumour cells. To test the hypothesis that curcumin exerts part of its chemopre-
ventive/anti-cancer effects by inhibiting the growth of tumour cells via inhibition of
NF-kB signalling, we examined the effects of curcumin on growth, IKK activity and
COX-2 or cyclin D1 expression in the COX-2 overexpressing colon tumour cell line
HCA-7. We also examined the effect of the NF-kB inhibitory peptide SN50 and its
inactive mutant SN50M on growth. Curcumin inhibited the growth of these cells (IC50
~5mM), without causing a reduction in COX-2 protein levels. SN50 also strongly
inhibited growth, but SN50M was inactive. Inhibition of growth by curcumin
appeared to involve down-regulation of cyclin D1, and correlated with direct inhibi-
tion of IKK (IC50 ~5mM). Curcumin’s growth inhibitory effects were partly accounted
for by induction of cell death which involved chromatin condensation and micronu-
cleation, but was distinguished from classical apoptosis by the lack of DNA laddering.
5.1
ACTIVATION OF THE PRO-APOPTOTIC PROTEIN BAK IS A TWO-
STEP PROCESS Bernard Corfe#, Gareth Griffiths#, Peter Savory,
John Hickman* & Caroline Dive, School of Biological Sciences, G38 Stopford
Building, University of Manchester, Manchester M13 9PT UK
We have used conformation-sensitive antibodies raised to two non-overlapping
domains of the pro-apoptotic protein Bak in order to investigate cell damage induced
changes in this protein. An N-terminal epitope of the pro-apoptotic protein Bak was
cryptic in untreated cells but exposed after diverse apoptotic stimuli (etoposide, heat
shock, taxol, dexamethasone or staurosporine) in CEM C7A and Jurkat T lymphoma
cells1. We identified a second conformational change in Bak protein using an antibody
raised against the central BH-1 domain. Exposure of this central epitope occurs after
the change observed at the N-terminus. Exposure of both the N-terminal and the
central epitopes was ZVAD resistant, implying that both either precede, or are inde-
pendent of, caspase activation. Co-immunoprecipitation studies using a polyclonal
antibody to Bak showed that Bak is bound to Bcl-xL in untreated cells. At early time-
points after drug treatment when the N-terminal epitope was exposed but the central
epitope remained occluded, Bcl-xL was bound to Bak. Subsequently, a decrease in
binding of Bak to Bcl-xL correlated with exposure of the central epitope. These data
imply that Bak is held bound to BclxL in untreated cells, that exposure of the N-
terminus of Bak occurs as a first step in the activation of its pro-apoptotic function,
prior to dissociation from BclxL. In marked contrast to other members of the Bcl-2
family (Bid, Bax, Bcl-xL and Bcl-2) where deletion of the N-terminus leads to an
increase in lethality, deletion of the Bak N-terminus caused a reduction its ability to
kill cells. This finding correlates with the absence of any reported Bak cleavage
product during apoptosis and may imply that an intact N-terminus of Bak plays a crit-
ical role in integrating damage signals. Taken together these data demonstrate the
existence of a two step process in the activation of Bak prior to apoptosis.
1 Griffiths GJ et al (1999) J Cell Biol 144: 903–914
#These authors contributed equally to this work.
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5.2
BAX ISOFORM EXPRESSION IN TUMOUR CELL LINES: LACK OF
ASSOCIATION WITH DRUG RESISTANCE AL Thomas*, SG Martin,
J Carmichael, and JC Murray, University of Nottingham Laboratory of
Molecular Oncology, CRC Department of Clinical Oncology, City Hospital,
Hucknall Road, Nottingham NG5 1PB, UK
The ability of a cell to avoid apoptosis in response to genotoxic stress is of central
importance in its progression to a malignant phenotype, and to the acquisition of drug
resistance in cancer. In the course of studies to examine the relationship between resis-
tance to apoptosis-inducing chemotherapeutic agents and expression of the pro-apop-
totic gene bax, we identified two new isoforms, which arise by alternative mRNA
splicing (AL Thomas et al. (1999) Cell Death Diff 6: 97). One of these isoforms, now
referred to as bax-w, contains all six exons found in the predominant form bax-a, and
in addition retains a partial 49 nucleotide sequence derived from an incompletely-
spliced intron 5. This isoform theoretically encodes a 24 kDa protein, lacking a trans-
membrane domain but containing the critical BH1-3 domains. We were able to
express this protein using in vitro transcription/translation assays, and to assess its
function by transiently over-expressing bax-w in Jurkat cells. The results demonstrate
that bax-w induces apoptosis at levels comparable to bax-a. The second isoform,
termed bax-e, encodes a polypeptide of ~1 kDa, the biological activity of which
remains unclear. We have evaluated the expression of these new isoforms, as well as
the better characterised isoforms bax-a and – d, in a range of tumour and normal cell
lines by RT-PCR, using isoform-specific primers. We found that only the JAR chorio-
carcinoma cell line consistently expressed all four isoforms bax-a, -d, -e, and -w. All
tumour cell lines examined, including K562 erythroleukaemia, MCF-7 breast adeno-
carcinoma, and HL60 promonocytic leukaemia cells expressed the -a and -w
isoforms. Normal fibroblasts and endothelial cells showed a similar pattern.
Expression of the bax-e isoform was observed in all these lines apart from K562. Of
particular interest were the NCI-460 non-small cell lung cancer cell line and its two
etoposide-resistant variants 460 v and 460pV8, since it was in one of these mutant
lines that we first detected the new bax isoforms. All three lines expressed bax-a and
-w, while only 460 v showed expression of bax-e. These data suggest that, in the case
of the NCI-460 cell line, resistance to the apoptosis-inducing agent etoposide is not
associated with expression of particular bax isoforms. The role of these new isoforms
of the pro-apoptotic gene bax, and of bax isoforms in general, remains unclear.
This work was supported by grants from the Cancer Research Campaign and Eli-
Lilly Pharmaceuticals
5.3
RESISTANCE TO TRAIL-INDUCED APOPTOSIS IN BURKITT’S
LYMPHOMA Amalia Mouzakiti* and Graham Packham, CRC Wessex
Medical Oncology Unit, Cancer Sciences Division, School of Medicine,
University of Southampton, Southampton, SO16 6YD, UK
The TRAIL-R (TNF related apoptosis inducing ligand receptors) DR4 and DR5 are
members of the TNF receptor superfamily and are potent inducers of apoptosis in
sensitive cells. These death receptors have attracted considerable interest because of
their involvement in apoptosis induced by chemotherapeutic agents and radiation, and
their potential for direct use in cancer therapies. Although normal cells are thought to
be resistant to TRAIL-induced apoptosis, the extent to which individual cancers are
sensitive to killing are not known. Potential mechanisms of resistance include muta-
tion/downregulation of DR4/DR5 expression, overexpression of non-functional
‘decoy’ receptors (DcR1 and DcR2) and altered expression of signalling intermedi-
ates (e.g., FADD, caspase-8) or inhibitors of signalling (e.g., FLIP). In this study we
investigated sensitivity to TRAIL-induced apoptosis in Burkitt’s lymphoma (BL) cell
lines.
We characterised the response to recombinant TRAIL of a panel of Epstein Barr
Virus (EBV)-positive and negative BL cell lines. Although the majority of lines
express the functional TRAIL receptors, DR4 and DR5, only a subset of EBV nega-
tive cell lines were highly sensitive to TRAIL-induced apoptosis. SSCP analysis of
the intracellular signalling domain of DR4 and DR5 did not reveal potential inacti-
vating mutations in resistant cell lines. Moreover, studies using isogenic BL lines
differing only in their EBV status, ruled out a direct role for EBV in determining resis-
tance to TRAIL. p53 and Bcl-2 family proteins are also unlikely to be key determi-
nants of sensitivity in BL cells, as the expression of Bcl-2 family proteins was
unrelated to resistance and stabilisation of p53 was not observed following treatment
with TRAIL. The expression of other modulators of TRAIL signalling (FADD,
caspase-8, FLIP and decoy receptors) did not correlate with responsiveness to TRAIL
cytotoxicity. In conclusion, our studies of BL cell lines demonstrate differential sensi-
tivity to TRAIL. However, the molecular determinants underlying TRAIL sensitivity
in BL remain to be determined.
5.4
EXPRESSION AND FUNCTION OF BCL-2 ASSOCIATED
ATHANOGENE-1, BAG-1, IN HUMAN BREAST CANCER CELL
LINES Paul A Townsend* and Graham Packham, CRC Wessex Medical
Oncology Unit, Cancer Sciences Division, School of Medicine, University of
Southampton, Southampton SO16 6YD, UK
BAG-1 is a multifunctional protein that associates with a range of cellular targets,
including the anti-apoptotic BCL-2 protein, the estrogen receptor (ER) and some
growth factor receptors. Direct interaction with 70 kDa heat shock proteins
(hsp/hsc70) may mediate these diverse associations. BAG-1 alters the in vitro chap-
erone function of hsp/hsc70 and suppresses apoptosis and regulates steroid hormone
dependent transcription. We previously demonstrated that BAG-1 is highly expressed
in a subset of invasive breast cancers and identified three distinct BAG-1 isoforms
generated by alternate translation of a single BAG-1 mRNA. Translation of the most
abundant BAG-1 isoform (p36 BAG-1) initiates at an internal AUG codon, whereas
larger BAG-1 proteins (p46 (BAG-1M) and p50 (BAG-1L)) initiate at upstream AUG
and CUG codons, respectively. The BAG-1 isoforms are differentially localised and
may therefore possess distinct functions. Since apoptosis and the ER are critical deter-
minants of the development and progression of breast cancer, it is important to under-
stand the mechanism of expression and functional role of these individual BAG-1
isoforms.
We characterised the expression of BAG-1 mRNA and protein isoforms in a panel
of eight human breast cancer cell lines using RNase protection assays and Western
blotting, respectively. We found a discordance between levels of protein and RNA
indicating an important level of post-transcriptional control. Using immunoprecipita-
tion of MCF7 cells stably overexpressing p36 BAG-1, we demonstrated a particularly
strong interaction with hsc70 relative to binding to BCL-2 and ER. Overexpression of
p36 BAG-1 completely suppressed the inhibition of clonogenicity of MCF7 cells
following transient heat shock. We are currently constructing a series of BAG-1
mutants and will test the ability of these molecules, as well as the other BAG-1
isoforms, to bind hsc70 and suppress heat shock responses in breast cancer cells.
Finally, we are constructing an inducible p36 BAG-1 expression system to investigate
directly the effects of BAG-1 on short-term effects of heat shock (e.g., cell cycle
arrest, apoptosis). These studies will help us to understand further the role of BAG-1
in breast cancer.
5.5
TRANSCRIPTIONAL CONTROL OF BCL-XL IN MALIGNANT
LYMPHOCYTES Lynn Wood*1, Lucy MacCarthy-Morrogh2 and
Graham Packham1, 1CRC Wessex Medical Oncology Unit, Cancer Sciences
Division, School of Medicine, University of Southampton, Southampton,
SO16 6YD, 2Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial
College School of Medicine, St. Mary’s Hospital, London W2 INY, UK
BCL-XL is an anti-apoptotic member of the BCL2 family of proteins. It plays a key
role in lymphocyte maturation and activation and is widely expressed in lymphomas.
Expression of BCL-XL in lymphoid cells is up regulated at the level of transcription
by survival signals such as CD40, IL-2 and IL-3. However the factors involved in
transcriptional control of BCL-XL expression are not fully understood. In this study
we investigated the expression of BCL-XL in lymphoma cells. Using 5¢-RACE
analysis we identified several BCL-XL mRNA structures and observed unexpected
complexity at the 5¢ non-coding portion of BCL-XL transcripts in human lymphoma
cells. Significantly, we identified a novel upstream non-coding exon (1B) spliced
directly to exon 2. This novel exon is derived from genomic sequences approximately
1 kb upstream from the previously published non-coding first exon of BCL-XL. A
candidate TATA sequence and consensus transcription factor binding sites were
located upstream of exon 1B supporting the possible usage of a previously uncharac-
terised promoter. mRNAs containing a second novel exon (1C) derived from
sequences within intron 1 were also identified. To examine cytokine induced regula-
tion of BCL-XL expression, IL-3 dependent 32D.3 murine myeloid progenitor cells
were used in a DEAE-dextran based transient transfection protocol. Luciferase
reporter assays demonstrated that IL-3 activation of the BCL-X promoter, following a
period of cytokine withdrawal, is dependent on a region 3.2–1.2 kb upstream of the
translation initiation site. This potential, murine IL-3 responsive promoter is located
within the same genomic region as the novel exon 1B we identified in human
lymphoma cells and does not contain the STAT binding sites recently reported to acti-
vate BCL-XL expression. We are currently fine mapping BCL-X promoter elements to
identify transcription factors important for BCL-XL expression in lymphoma cells and
in response to survival signals. Our findings suggest that the regulation of BCL-XL
transcription in malignant lymphocytes may differ from that in normal lymphocytes
and involve usage of variant exons and promoters. Existence of separate transcrip-
tional control mechanisms for BCL-XL in malignant lymphocytes potentially could be
manipulated in the development of therapies to treat lymphomas.22 Oral Presentations
5.6
ASSESSMENT OF MITOCHONDRIAL DNA DAMAGE BY
CHEMOTHERAPEUTIC AGENTS SK Lo, B Tolner, G Rogers, AHV
Schapira, JA Hartley and D Hochhauser, Dept of Oncology and Neurology,
Royal Free and University College Medical School, UCL, 91 Riding House
St., London W1P 8BT, UK
The mitochondrial genome consists of a double-stranded circular molecule of 16.5
kilo bases encoding 37 genes; 2 rRNAs, 22 tRNAs and 13 polypeptides all of which
are subunits of enzyme complexes of the oxidative phosphorylation system. It has
been reported that cancer cells contain greater numbers of mitochondria and exhibit an
increased mitochondrial membrane potential. This could be exploited in targeting
tumour cells using charged molecules such as lipophilic cations which show preferen-
tial uptake by mitochondria. The rhodocyanine analogue MKT 077 which has been
demonstrated to directly damage mitochondrial DNA (mtDNA) is undergoing evalua-
tion as an anticancer drug. The aim of this study was to investigate the effect of
chemotherapeutic agents including MKT 077 on mtDNA damage. For these experi-
ments, two cell lines were used; A549 a non small cell lung cancer and its rho 0 deriv-
ative which is devoid of mtDNA. Upon exposure to Daunoblastin (an anthracycline)
or MKT 077 the rho 0 cell line was found to be approximately 10 fold more resistant
to both agents when analysed with a cell proliferation assay (Sulforhodamine B).
Immunoblotting demonstrated no difference in p53 or topoisomerase IIµ expression
between the cell lines. The involvement of P-glycoprotein was excluded since
Daunoblastin uptake was similar in both cell lines as shown by flow cytometry
analysis. Southern blot experiments using probes specific for genomic and mitochon-
drial genes revealed that following treatment with Daunoblastin or MKT 077, there
was preferential damage to mtDNA at concentrations of drug in which no nuclear
DNA damage was demonstrable. Flow cytometry analysis following treatment with
MKT 077 showed a G2 arrest of A549 cells whereas at similar drug concentrations
there was no alteration in cell cycle distribution in rho 0 cells. This suggest that
mtDNA damage may lead to cell cycle alteration. A fusion cell line was produced by
introducing mtDNA from wild type A549 cells into the rho 0 cell line; this restored
the chemotherapeutic sensitivity to that comparable with the parental cell line. In
summary, we have demonstrated that mtDNA is susceptible to damage by cytotoxic
agents and that mtDNA may represent a novel target for chemotherapeutic agents.
5.7
PRECLINICAL PHARMACOLOGY OF A NOVEL CLASS OF BCL-2
RESISTANT CHEMOSENSITISER WITH AFFINITY FOR THE
MITOCHONDRIAL BENZODIAZEPINE RECEPTOR 1DA Fennell, 1A Okaro,
1M Corbo, 2DE Banker, 2F Applebaum, 1FE Cotter, 1St Bartholomew’s & The
Royal London Medical School, Turner Street, London, UK, 2The Fred
Hutchinson Cancer Research Center, Seattle, USA
Mitochondria play a critical role in regulating commitment to apoptosis, a process
underlying the efficacy of most anti-cancer therapies. Resistance mediated at the
mitochondrial level by overexpression of Bcl-2 and/or its anti-death homologues
limits therapeutic efficacy. We have investigated ligands of the 18 k Dalton mitochon-
drial benzodiazepine receptor (mBzR) which co-localises the mitochondrial perme-
ability transition pore complex (PTPC), a target for both pro- and anti-death
homologues of the Bcl-2 family. The mBzR ligand PK11195 was shown to facilitate
chemotherapy induced mitochondrial inner membrane depolarisation (using
DiOC6(3)-propidium iodide flow analysis) and apoptosis (Z.DEVD.fmk inhibitable
plasma membrane unpacking) in a wide range of haemopoietic and solid tumour cell
lines shown to express the mBzR using the fluorochrome, NBD FGIN-1–27 analogue.
Intrinsic cytotoxic efficacy was not observed. Ex-vivo potentiation of etoposide
induced apoptosis was observed in Bcl-2 hyperexpressing lymphoma xenografts after
in vivo treatment with PK11195 and the mBzR ligand NF49. Furthermore, growth
retardation and regression were observed in cholangiocarcinoma (TFK-1, EGI-1) and
haemopoietic (BV173) xenografts respectively as early as 72 hours after treatment. At
the subcellular level, PK11195 induced rapid mitochondrial biogenesis secondary to
induction of reactive oxygen species (ROS) that was inhibitable by antioxiants, but
not deletion of the mitochondrial respiratory chain. ROS production was temporally
associated with inhibition of glycolytic flux. Cellular levels of reduced non-protein
thiols but not Bcl-2 expression, determined cellular sensitivity to PK11195 underlying
the importance of its pro-oxidant activity. In summary, mBzR ligands represent a new
class of chemosensitiser with clinical potential in the treatment of malignancy.
5.8
PK11195, A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
ANTAGONIST RADIOSENSITIZES BCL-XL AND MCL-1
EXPRESSING CHOLANGIOCARCINOMA TO APOPTOSIS MC Okaro*1&2,
DA Fennell2, FE Cotter2, BR Davidson1, 1University Dept Surgery RF &
UCMS London NW3 2PF & 2Dept Exp. Hematology, St. Barts and The RLS
of Medicine London E1 2AD, UK
Inoperable cholangiocarcinoma responds poorly to chemotherapy and radiotherapy.
DNA damage with the induction of apoptosis following chemotherapy and radio-
therapy plays a major part in the mode of action of these forms of cancer treatment.
The mitochondria have emerged as key players in apoptosis. Members of the bcl-2
family of apoptosis regulating proteins that localize to the mitochondria play an
important role in apoptosis through regulating the release of cytochrome c from the
intermembrane space. High levels of bcl-xL and mcl-1 proteins are localized to mito-
chondria in cholangiocarcinoma, but their role in the control of apoptosis in this
disease remains unknown.
Using Pk11195 a mitochondrial benzodiazepine receptor antagonist that is known
to block the cytoprotective effects bcl-2. We investigated the role the highly expressed
mitochondrial bcl-xL and mcl-1 proteins in Egi-1 and Tfk-1 (two human cholangio-
carcinoma cell lines) played in radioresistance of cholangiocarcinoma, by studying
the effects blocking mitochondrial bcl-xL, and mcl-1 with Pk11195 had on the
response of Tfk-1 and Egi-1 to UV Irradiation and 50–1000 cGy of radiotherapy over
72 hrs.
Apoptosis was monitored through measuring the collapse in the inner mitochon-
drial membrane potential (DYm) detected at single cell resolution by flow cytometry
using the DYm sensitive lipophilic flourochrome DiOC6(3) and by the annexin V assay.
We found that inhibiting mitochondrial bcl-xL and mcl-1 in cholangiocarcinoma
cells sensitizes them to UV light and radiotherapy induced apoptosis which was dose
and time dependent. Pk11195 alone had no intrinsic apoptosis inducing effects over 96
hours on either cell line.
Antagonizing the function of the anti-apoptotic bcl-2 proteins at the mitochondria
sensitizes cholangiocarcinoma cells to radiotherapy. Expression of these proteins in
this disease may explain the low efficacy of radiotherapy in this disease.
6.1
MULTIPLE FUNCTIONS OF THE PTEN TUMOUR-SUPPRESSOR
PROTEIN IN HUMAN PROSTATIC CELL LINES R Michael
Sharrard* and Normal J Maitland, YCR Cancer Research Unit, Department
of Biology, University of York, York YO10 5YW, UK
The tumour suppressor protein PTEN has been characterised as a phosphatase with
both protein and lipid substrates. Its activities have been predicted to influence cell
motility, adhesion and spreading via integrin-activated cellular mechanisms as well as
regulating cell proliferation and survival through dephosphorylation of phosphatidyl-
inositol-3,4,5-trisphosphate and related compounds.
Since the PTEN gene is frequently inactivated in prostate cancers, we investigated
the function of PTEN phosphatase activities in human non-tumour (PNT2, PNT1a)
and tumour (LNCaP, PC3) cell lines using constructs expressing wild-type (wt) PTEN
or PTEN mutants G129E (lacking lipid phosphatase), G129R (lacking lipid and
protein phosphatases), and C124A (phosphatase-null mutant). We also used Flag-
epitope tagged and EGFP-conjugated forms of these variants. Analysis of transiently-
and stably-transfected cells by immunocytochemistry and Western blotting demon-
strated that PTEN affects cell adhesion and survival through as yet uncharacterised
activities additional to both phosphatase activities. Modification of either N- or C-
termini of PTEN dramatically altered its stability and function, potentially through
effects on interaction with docking or modifying molecules.
Stable overexpression of exogenous wt PTEN was lethal to the LNCaP and PC3
tumour cell lines, which lack endogenous wt PTEN, but not to the non-tumour cell
lines, indicating that one or more signalling pathways controlled by PTEN are altered
in the tumour cells. The effects of transfection with wt PTEN on the PKB/Akt
pathway differed between the cell lines depending on the extent to which Akt phos-
phorylation could be inhibited solely through blockade of the P13-kinase. Further
evidence of differential responses of the downstream targets of PTEN was provided
by the effects of both serum starvation and the P13-kinase inhibitor LY294002.
We conclude that PTEN has multiple functions in prostatic cells, including effects
mediated through the lipid phosphatase and the PKB/Akt pathway, through the protein
phosphatase, and through other, presently uncharacterised functions. The extent to
which PTEN affects cell growth and survival through these different pathways may
differ between different androgen-dependent and -independent tumour cell lines as
well as between tumour and non-tumour cells. Analysis of the functional domain
structure of PTEN will allow the design of modified PTEN molecules for targeting
specific regulatory pathways implicated in the growth and survival of prostate tumour
cells. In combination with suitable delivery systems, the use of PTEN variants with
enhanced intracellular stability and specifically modified functions may have impor-
tant potential in gene therapy for prostate and other cancers.Oral Presentations 23
6.2
RNA POLYMERASE III TRANSCRIPTION – ITS CONTROL BY
TUMOUR SUPPRESSORS AND ITS DEREGULATION IN
CANCERS S Allison, T Brown, C Cairns, Z Felton-Edkins, C Larminie, A
McLees, P Scott, G Sourvinos, T Stein, J Sutcliffe, K Tosh, A Winter and R
White*, Institute of Biomedical and Life Sciences, University of Glasgow,
Glasgow, UK
The level of protein synthesis is a critical determinant of the rate of cellular growth.
Abnormal activation of this process is a frequent feature of transformed and tumour
cells. Since translation is restricted if rRNA or tRNA levels are limiting, the synthesis
of these products may need to increase to allow the rapid growth of tumours. RNA
polymerase III (pol III) is responsible for producing tRNA and 5S rRNA. A wide
range of transforming agents stimulate pol III transcription. Our work aims to charac-
terize the mechanisms responsible.
We have shown that the tumour suppressor RB binds and represses the pol III-
specific transcription factor TFIIIB (1,2). Many of the molecular details of this regu-
lation are now understood. RB function is lost in cancer through one of three different
mechanisms: mutation of the Rb gene; binding of oncoproteins; or phosphorylation by
cyclin-dependent kinases; we have evidence to show that each of these mechanisms
can result in elevated pol III activity in vivo (3).
Release of TFIIIB from repression by RB is likely to contribute to the deregulation
of pol III in many tumours. However, additional mechanisms are also involved. For
example, TFIIIB is also bound and repressed by wild-type p53 (4); mutations in p53
can release TFIIIB from an important restraint, both in tumours and in untransformed
fibroblasts from patients with Li-Fraumeni syndrome. TFIIIB is recruited to
promoters by the DNA-binding factor TFIIIC2. TFIIIC2 is a complex of five separate
subunits, all of which are overexpressed together in some gynaecological tumours;
this provides another route towards the aberrant activation of pol III transcription.
Deregulation of pol III is therefore a very common feature of cancer that can involve
several distinct regulatory mechanisms.
1 White RJ, Trouche D, Martin K, Jackson SP and Kouzarides T (1996) Nature
382: 88–90
2 Larminie CGC, Cairns CA, Mital R, Martin K, Kouzarides T, Jackson SP and
White, RJ (1997) EMBO J 16: 2061–2071
3 Larminie CGC, Sutcliffe JE, Tosh K, Winter AG, Felton-Edkins ZA and White
RJ (1999) Mol Cell Biol 19: 4927–4934
4 Cairns CA and White RJ (1998) EMBO J 17: 3112–3123
6.3
TRUNCATING MUTATIONS OF THE EP300 ACETYLASE IN
HUMAN CANCERS Simon A Gayther*1,3, Paul Russell1,3, Bruce AJ
Ponder1,3,4, Tony Kouzarides2,5 and Carlos Caldas1,4, Departments of
Oncology1 and Pathology2, and Strangeways Research Laboratories3,
Cambridge Institute for Medical Research4 and Wellcome/CRC Institute5,
University of Cambridge, Cambridge CB2 2XY, UK
EP300 is a histone acetyltransferase that regulates transcription via chromatin remod-
elling. It plays an important role in the processes of cell proliferation and differentia-
tion, and interacts with and acetylates p53 in response to DNA damage. This
modification regulates the DNA binding and transcription functions of p53. A role for
EP300 in cancer has been implied by the fact that it is targeted by viral oncoproteins
and that it is fused to MLL in leukaemia. Nevertheless direct demonstration of the role
of EP300 in tumorigenesis by inactivating mutations in human cancers has been
lacking. Here we describe EP300 mutations which are predicted to result in a trun-
cated protein in 6 (3%) of 193 epithelial cancers analysed. Of these six mutations, two
were in primary tumours (in a colorectal cancer and in a breast cancer), and four were
in cancer cell lines (colorectal, breast, and pancreatic). In addition, a somatic in-frame
insertion in a primary breast cancer, and missense alterations in a primary colorectal
cancer and in two cell lines (breast and pancreatic), were identified. Inactivation of the
second allele could be demonstrated in 5 of the 6 cases with truncating mutations, and
in 2 of the other cases. Truncated EP300 was shown to be stably expressed in cell lines
with EP300 mutations by western blotting. Finally, immunohistochemical analysis
suggests that EP300 expression is frequently reduced or absent in breast and ovarian
tumours. Together, these data show that EP300 is mutated in epithelial cancers and for
the first time provide unequivocal evidence that it behaves as a classical tumour
suppressor gene.
6.4
PPARg EXPRESSION IN THE NORMAL AND NEOPLASTIC
HUMAN BLADDER AND PROSTATE AND ITS POTENTIAL AS A
NOVEL THERAPEUTIC TARGET MC Jarvis*, MC Bibby, TA Baokbah, NB
Hussain, S Ganta and MJ Thompson, Clinical Oncology Unit, University of
Bradford, West Yorkshire BD7 1DP, UK
Prostate cancer is the second most common male cancer in the U.K. Most patients
present with androgen dependent tumours, which are treated by the withdrawal of
androgen. However many relapse into an androgen independent form, for which
currently there is no effective treatment. Bladder cancer is a predominantly male
disease. It is initially treated by surgery but has a poor five-year survival rate.
Improvements on these figures rely on the development of new adjuvant therapies.
The induction of differentiation may offer a novel, alternate approach to the treatment
of these types of cancer.
The peroxisome proliferator-activated receptor gamma (PPARg) belongs to the
nuclear receptor superfamily of ligand-activated transcription factors. It has a distinct
regulatory role in modulating lipid homeostasis and promoting differentiation.
Prostate and bladder tissues were examined for the possible expression of this
receptor. Although its function within these, is unknown.
Initially immunostaining was employed to define the distribution of PPARg within
the human urogenital system. Expression of PPARg was found to be predominantly in
the nucleus. Smooth muscle and basal cells of normal prostatic epithelium express the
receptor. The majority of androgen responsive (12/13) and androgen unresponsive
(7/10) prostate tumours were also shown to stain positively for PPARg. In the normal
bladder the receptor is confined to the nuclei of the urothelium, lamina propria and
smooth muscle. 8/9 sections taken from transitional cell carcinomas of the bladder
were found to express PPARg. Western blots on three bladder tumour cells lines, RT4,
T24/83 and RT112 confirmed a band at the correct molecular weight for PPARg (48
kDa). The chemosensitivity of these three bladder tumour cells to troglitazone
(C24H27NO5S), a thiazolidinedione agent and selective ligand for PPARg was
measured by the MTT assay. The IC50 values for the assay of RT4, T24/83 and RT112
against troglitazone were calculated to be 5.21, 28.74 and 22.35 mM respectively. This
indicates that in all lines studied, this specific ligand has a significant effect on cell
growth.
The results demonstrate that PPARg may be a useful, additional therapeutic target
for the treatment of some common male urogenital cancers.
This work is supported by War on Cancer and Johnson Matthey by the Kevin
Gibbons Award.
6.5
ROLE OF E2F-1 IN CHEMOSENSITIVITY TO MINOR GROOVE
BINDING AGENTS C Hampel1, B Tolner1, SD Webley1, E Lam2, JA
Hartley1 and D Hochhauser1, 1Royal Free and University College Medical
School, University College London, 91, Riding House Street, London W1P
8BT, 2Ludwig Institute, St Mary’s Hospital London, UK
The E2F transcription factors are critical genes involved in cell cycle progression and
have been implicated in apoptosis. Previous studies indicated that cell lines overex-
pressing E2F-1 exhibited an altered chemosensitivity to chemotherapeutic agents such
as 5-fluorouracil, etoposide and doxorubicin (Banerjee et al., 1998 Cancer Research
58, 4292–4296). The aim of the current study was to investigate mechanisms under-
lying the differential chemosensitivity of a stably transfected E2F-1 overexpressing
HT1080 fibrosarcoma cell line to chemotherapeutic agents. Two clones were selected
with approximately 3–5 fold increased E2F-1 expression as assessed by Western blot-
ting, compared to the HT1080 control cell line, transfected with the neomycin resis-
tance gene. Electrophoretic mobility shift assay and antibody supershift experiments
confirmed increased E2F-1 expression as well as indicating complex formation
between E2F-1 and the pocket proteins p130 and p107. No difference in cytotoxicity
was observed between the control and E2F-1 overexpressing lines with cisplatinum
and melphalan. Growth inhibition studies (sulphorodamine B assay) with BGIII21, a
DNA sequence specific minor groove alkylating agent, revealed that E2F-1 overex-
pressing clones were >8 fold and >70 fold resistant after 1 hour and 72 hour incuba-
tion, respectively, compared to the control cell line. The E2F-1 overexpressing cell
line was found 3–5 fold less active to other minor groove binding agents such as
Hoechst 33258 and anthramycin compared to the control. Clonogenic assays exhib-
ited increased numbers of colonies compared to the control following exposure to
BGIII21. Cell cycle analysis and apoptosis assay, at a dose of BGIII21 corresponding
to the IC50 resulted in induction of cell cycle arrest at the G2 – S phase after 48 hours,
followed by apoptotic death in the control cell line. In contrast, cells overexpressing
E2F-1 showed neither change in cell cycle distribution nor evidence of apoptosis
following drug treatment. Single-strand-ligation-PCR (Sslig) assays are being carried
out to investigate whether E2F-1 is implicated in the repair of BGIII21 lesions and
whether downstream pathways are affected.24 Oral Presentations
6.6
BARX2: A TUMOUR PROGRESSION-SUPPRESSOR AND
MODULATOR OF CISPLATIN RESISTANCE IN OVARIAN CANCER?,
H Gabra*1, G Sellar1, Li Li1, K Watt1, B Nelkin2, G Rabiasz1, E Miller1, D
Porteous3 and JF Smyth1, 1ICRF Medical Oncology Unit, Western General
Hospital, Edinburgh EH4 2XU, 2Oncology, Johns Hopkins University School
of Medicine, Baltimore MD 21231, 3Molecular Medicine Centre, University of
Edinburgh, Western General, Hospital, Edinburgh EH4 2XU, UK
We have previously reported that frequent loss of heterozygosity (LOH) at 11q24 is
associated with poor survival in epithelial ovarian cancer. Microcell mediated chro-
mosome transfer of human chromosome 11 into ovarian cancer cell line OVCAR3
was associated with inhibition of matrigel invasion, transwell migration and cell adhe-
sion.
Human BARX2, initially identified as a ras responsive transcription factor, is
homologous to the Drosophila bar class of homeobox genes. We have further refined
the location of BARX2, linking it to D11S4131 by GB4 radiation hybrid mapping and
physically mapping it to the interval D11S912-GCT17D11.
Northern analysis showed absent BARX2 expression in ovarian cancer cell lines
OA W42 and A2780, although genomic PCR showed all exons to be intact.
Expression in sequential series of cell lines derived from two patients showed loss of
BARX2 expression associated with cisplatin resistance in both patients.
Two mis-sense mutations have been identified in a panel of cancer cell lines. Both
are contained within exon 2, 5¢ of the homeodomain. The 5¢ end of the gene is methy-
lated in a number of cancer cell lines as demonstrated in MspI/HpaII Southern blots,
suggesting a possible mechanism for gene silencing.
Transfection of full length BARX2 cDNA into OA W42 confers in-vitro suppres-
sion of growth, migration, adhesion to collagen and matrigel invasion. FACS analysis
demonstrates that transfection results in S-phase block. However OA W42 clono-
genicity is unaltered in colony formation assays. Azacytidine mediated demethylation
results in re-expression of BARX2, suggesting that methylation-silencing is a mecha-
nism of inactivation in this cell line.
BARX2 transfection completely reverses acquired cisplatin resistance in PEO1-
CDDP, with no such effect on the PEO1 sensitive parent line.
6.7
cDNA ISOLATION, CHROMOSOMAL LOCALISATION, AND
BIOCHEMICAL CHARACTERISATION OF THE CANDIDATE
HUMAN ONCOGENE, FIBULIN-4 WM Gallagher*1, LM Greene1, SM
Strachan1, MP Ryan1, V Sierra2, L Debussche2, E Conseiller2, 1Conway
Institute, Department of Pharmacology, University College Dublin, Ireland;
2Oncology Department, Rhône-Poulenc Rorer, France
Fibulins are an emerging family of extracellular matrix proteins that have been impli-
cated in a variety of biological processes, including tissue remodelling and fibrogenesis.
Certain fibulins may influence tumour development through regulation of tumour cell
growth, motility, invasion, along with angiogenesis. Fibulin-4, also known as MBP 1,
has been shown previously to display both mutant p53-dependent and -independent
oncogenic propertiesa. In addition, fibulin-4 provides new insight with respect to the
mutant p53 ‘gain of function’ phenotype, a controversial phenomenon that might have
important implications for both cancer biology and therapeutic intervention. Mouse
fibulin-4 was originally identified by this research groupa. Here, we describe the cDNA
isolation, chromosomal localisation and biochemical characterisation of human fibulin-
4. Firstly, we carried out a search for human expressed sequence tags (ESTs) which
displayed greater than 85% homology with the mouse fibulin-4 cDNA sequence. Using
information derived from overlapping human ESTs combined with PCR-based cloning,
we isolated the entire human fibulin-4 cDNA. Expression of human fibulin-4 mRNA, as
determined by Northern blot analysis, was shown to be differentially regulated in a
tissue-specific manner, e.g. with a high level of expression in heart, ovarian and colon
tissues, with very low levels of fibulin-4 mRNA in the brain and liver. Using the tech-
nique of fluorescence in situ hybridisation (FISH), the human fibulin-4 gene was
localised to the distal portion of chromosome 11 band q13, which is a genomic region
exceptionally rich in genes and disease-related genetic loci. Moreover, portions of 11q13
are frequently amplified in many common tumours, including breast and oesophageal
cancer. In vitro transcription/translation of fibulin-4 cDNA produced a recombinant
protein of ~54 kDa. Through the additional use of canine microsomal membranes
(CMMs) with standard in vitro transcription/translation reactions, one can also stimulate
sequence-directed co- and post-translational processing events, such as membrane
translocation, signal sequence cleavage and N-glycosylation. Using CMMs, we
revealed that fibulin-4 protein is most likely inserted into the lumen of the endoplasmic
reticulum and is N-glycosylated. These results are in agreement with the presence of a
putative signal sequence at the N-terminus of fibulin-4, along with two candidate N-
glycoslyation sites located in the centre of the protein. Finally, a pilot study using a panel
of nine paired human colon tumour/normal tissue biopsies revealed up-regulation of
fibulin-4 mRNA, as determined by semi-quantitative RT-PCR, in five of these tumours
relative to normal tissue obtained from the same patient. This is consistent with a poten-
tial role for fibulin-4 in tumourigenesis, as a candidate oncogene.
a Gallagher WM, Argentini M, Sierra V, Bracco L, Debussche L and Conseiller E
(1999) Oncogene 18: 3608
6.8
CYCLOOXYGENASE-2, PROSTAGLANDIN-E2,
MALONDIALDEHYDE AND MALONDIALDEHYDE-DNA ADDUCTS
IN HUMAN COLONIC CELLS RA Sharma*1, SM Plummer2, C Leuratti2, R
Singh2, B Gallacher-Horley2, LJ Marnett3, A Gescher2 and WP Steward1,
1Department of Oncology and 2MRC Toxicology Unit, University of Leicester,
Leicester LE1 9HN and 3Vanderbilt Cancer Center, Nashville, TN 37232,
USA
Cyclooxygenase-2 (COX-2), an enzyme pivotal for prostaglandin (PG) biosynthesis,
has been implicated in the pathogenesis of colorectal cancer (CRC). Malondialdehyde
(MDA), a mutagen produced by lipid peroxidation and during PG synthesis, forms
DNA adducts, predominantly with deoxyguanosine (M1-G). Elevated levels of MDA
in CRC tissue appear to correlate with levels of PG-E2
1. Here the hypothesis was
tested that COX-2 activity contributes to the development of the malignant phenotype
via generation of M1-G adducts. M1-G levels, determined by immunoslot blot2, in non-
malignant human colon epithelial (HCEC) cells and malignant colon lines SW48,
SW480, HT29 and HCA-7, varied between 77 and 148 adducts per 108 nucleotides.
Adduct levels in HCEC cells could be increased by 24-hour incubation with chemi-
cally synthesized MDA. Only HCA-7 and HT29 cells expressed COX-2 protein as
adjudged by Western blotting. Basal levels of M1-G correlated significantly with those
of MDA determined colorimetrically in the four malignant cell types (r=0.98.
p<0.001), but neither correlated with expression of COX-2 or PG-E2. Induction of
COX-2 expression in HCEC cells by 75 nM phorbol 12-myristate 13-acetate caused
an increase in intracellular MDA from 0.38±0.12 to 1.07±0.32 nmol/mg protein after
4 hours, but did not alter M1-G adduct levels after 4, 24 or 72 hours. Selective inhibi-
tion of COX-2 activity in HCA-7 cells by incubation with 17.7 mM NS-398 for 24
hours did not alter MDA nor M1-G levels, despite decreasing PG-E2 levels from
10.7±2.1 to 1.3±0.6 ng/106 cells. These results do not support a causal link between
COX-2 activity and M1-G adduct levels in the mechanism of CRC development. They
represent independently regulated variables which merit separate investigation as
potential biomarkers of efficacy in chemoprevention trials.
1 Hendickse CW et al (1994) Brit J Surg 81: 1219
2 Leuratti C et al (1998) Carcinogenesis 19: 1919
7.1
ASSOCIATION BETWEEN POLYMORPHISMS OF THE GPX1
GENE AND MULTIPLE PRIMARY TUMOURS OF THE HEAD AND
NECK S Jefferies*1, Z Kote-Jarai1, R Houlston1, M-J Frazer–Williams1, R
A’Hern2, MPT Collaborators and R Eeles1
Head and neck cancer (SCCHN) is a common cancer. For many years it has been known that
the major aetiological factors are tobacco and alcohol exposure and little attention has been
paid to other predisposing factors. There is now some preliminary evidence that there may be
a genetic component to SCCHN. Individuals who have had an index squamous cell cancer of
the head and neck (SCCHN) have a 10–20% chance of developing a second primary tumour
(MPT). There is an increased risk of cancer in first-degree relatives of individuals with
SCCHN and this risk rises markedly when the affected individual has had two primary
tumours. Individual susceptibility to cancer development may be contributed to by differences
in metabolism of carcinogens. The human cellular glutathione peroxidase I (GPX1) is a sele-
nium-dependent enzyme that protects against oxidative damage. Dietary selenium has been
implicated in the possible chemoprevention of some cancers. The GPX1 gene maps to chro-
mosome 3p21, an area frequently showing loss of heterozygosity in SCCHN. There are three
GPX1 alleles characterized by number of GCG triplet nucleotide repeats encoding for alanine
in a polyalanine tract in exon 1. The GPX1 alleles with five or seven alanines are identical
except for the length of the polyalanine polymorphism. The GPX1* ALA6 also has a leucine
for proline substitution at codon 198, a T for C substitution at +2 and a G for A substitution at
–5921. The effect on function of each of these polymorphisms of the GPX1gene is not known.
We investigated the association between the genetic polymorphisms in the GPX1gene and
patients with index squamous cell cancer of the head and neck who developed second primary
tumours compared with population controls. The genotypes were determined for 63 cases of
MPT and 259 controls using a PCR technique with a fluorescent-labeled primer. The PCR
products were analysed using an AB1 automated fluorescent DNA sequencer. The associa-
tions between specific genotypes and the development of MPT were examined by the Chi-
squared test.
We found a significantly increased frequency of the GPX1*ALA6/GPX1*ALA7 genotype
in the MPT cases versus controls (P=0.05). The findings of this study suggest that the
GPX1*ALA6/GPX1*ALA7 genotype may be associated with an increased risk of developing
second primary cancers. The identification of such genotypic markers may be of value in the
future for targeting chemoprevention towards individuals at high risk of developing a second
malignancy.
MPT Collaborators: J Henk2, M Gore2, P Rhys-Evans2, D Archer2, K Bishop2, E Solomon3,
S Hodgson3, M McGurk3, J Hibbert3, M O’Connell3, M Saunders4, M Partridge3, E
Chevretton3, F Calman3, K Shotton5, A Brown6, S Whittaker7, D Goldgar8, W Foulkes9.
1Cancer Genetics, Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey. 2The Royal
Marsden Hospital Trust, Downs Rd, Sutton, Surrey, SM2 5PT. 3 Guys and St Thomas’ and
Kings Hospital Trusts. 4Mount Vernon Hospital Trust, Rickmansworth Road, Northwood,
Middlesex, HA6 2RN. 5Mid-Kent Oncology Centre, Hermitage Lane, Maidstone, Kent, ME16
9QQ. 6Queen Victoria Hospital, East Grinstead. 7Royal Surrey County Hospital, Egerton Road,
Guildford, GU2 5XX. 8IARC, Lyon, France. 9McGill University, Montreal, Canada.
1 Moscow et al (1994) Carcinogenesis 15: 2769–2773Oral Presentations 25
7.2
BRCA1, BRCA2 MUTATION AND PEDIGREE GENETIC ANALYSIS
TO DETERMINE GENETIC RISK IN THE UK ROYAL MARSDEN
HOSPITAL TAMOXIFEN PREVENTION TRIAL RA Eeles1,2, TP Powles2, S
Ashley2, DF Easton3, L Assersohn2, N Sodha2, M Dowsett1, B Gusterson1, A
Tidy2, G Mitchell1,2, Z Kote-Jarai1, 1) Institute of Cancer Research, Sutton,
Surrey, SM2 5NG, UK; 2) Royal Marsden NHS Trust, Sutton, Surrey SM2
5PT, UK; 3) CRC Genetic Epidemiology Unit, Strangeways Research
Laboratories, Cambridge, CN1 4RN, UK
In the Royal Marsden Hospital tamoxifen prevention study, 2500 women at increased
risk of developing breast cancer because of a family history of the disease were
randomised to receive tamoxifen 20 mg daily or placebo for 8 years. 70 women devel-
oped primary breast cancer, 36 whilst on placebo, 34 on tamoxifen. Family history out
to at least 2nd degree relatives was taken from all women in the study. DNA from
peripheral blood from 67 of the 70 women was analysed for coding mutations in the
BRCA1 and BRCA2 genes by CSGE analysis of the entire coding region of both
genes. 6 mutations were found, 2 in BRCA1 and 4 in BRCA2, 4 would be expected to
be pathogenic as these were nonsense/frameshifts. 2 were rare variants which were
not present in 100 normal controls. The posterior probability of carrying a breast
cancer predisposition gene in the individuals who developed breast cancer was
assessed using the Cyrillic genetic risk package, based on the Claus model (Claus et
al., 1991*). 26 women had <50% posterior probability of harbouring a breast cancer
predisposition gene and 44 had a ³50% chance of having a breast cancer predisposi-
tion gene. In the former group of 26 women, 8 had been taking tamoxifen and 18
placebo. In the group of women with ³50% probability of having a breast cancer gene,
26 had been taking tamoxifen and 18 placebo. The differences between the numbers
of women taking tamoxifen who subsequently developed cancer in the two groups
divided by <50% or ³50% genetic risk was significant at p = 0.04. These preliminary
data suggest that tamoxifen prevention maybe more effective in women with a <50%
chance of harbouring a breast cancer predisposition gene.
*Claus et al (1991) Am J Epidemiol 48
7.3
BRCA2 MUTATIONS IN A SCOTTISH MALE BREAST CANCER
POPULATION IE Young*1, MAF MacKenzie1, KM Kurian1, C Annink1,
JMV Back1, IH Kunkler2, BB Cohen3, CM Steel3, 1/C.R.C. Laboratories,
Molecular Medicine Centre & 2/Dept. of Clinical Oncology, Western General
Hospital, Crewe Road, Edinburgh, EH4 2XU, 3/School of Biomedical
Sciences, University of St. Andrews, St. Andrews, Fife KY16 9TS, UK
Male breast cancer is a rare disease, accounting for approximately 1% of total cases of
breast cancer. Mutations of the BRCA1 and BRCA2 tumour suppressor genes have
been identified in some cases of familial and early onset breast cancer. Male breast
cancer has been linked to mutations of the BRCA2 gene in some cases. The aims of
this study were to construct family pedigrees and to identify mutations in the BRCA2
gene in a group of male breast cancer patients from the South East of Scotland.
Cases were a consecutive series of 76 male breast cancer patients treated in S.E.
Scotland between 1974 and 1998. 64 DNA samples were available (from blood
samples in 25 cases, archival tissue in 39). Family pedigrees were constructed for all
cases where possible by an experienced genealogist.
The entire coding region and splicing sites of BRCA2 were amplified by PCR
using 62 pairs of primers (designed by Dr. R. Wooster). These PCR products then
underwent heteroduplex analysis (HA). Protein truncation testing (PTT) was also
performed for exons 10, 11 and 27. PCR products showing variant bands on HA or
PTT were reamplified from genomic DNA and cycle sequenced.
Germline BRCA2 mutations were identified in 12 of the 64 (19%) male breast
cancer cases. This frequency is higher than that previously reported from the UK
(7%)[1] or USA (4–14%)[2][3], suggesting that germline BRCA2 mutations may account
for a relatively high proportion of male breast cancer cases in Scotland. Six of the 12
cases (50%) had a history of female breast cancer in a first- or second-degree relative.
38 of the 61 male breast cancer patients tested (62%) carry a polymorphism in
BRCA2 exon 2 (203 G®A). 52 of 116 male and female controls (45%) carry this
polymorphism. The difference between cases and controls is statistically significant
(p=0.0272, c2=4.88, 1 df). The odds ratio for the risk of a male with the exon 2 poly-
morphism developing breast cancer is calculated as 2.03 (95% CI 1.08–3.83).
Previous studies have found the frequency of the exon 2 polymorphism to be only
17–22% in control and male breast cancer populations. All three male breast cancer
cases found to have a mutation in exon 16 (7830 del 16 bp, the commonest mutation
found in this study) also carry the exon 2 polymorphism, perhaps indicating linkage
disequilibrium. Alternatively, the exon 2 polymorphism may in some way alter the
transcription of the BRCA2 gene. This would be an interesting area that we intend to
explore further because it may provide further insight into how BRCA2 is involved
with the development of male and female breast cancer.
1 Mavraki et al (1997) Br J Cancer 76:(11) 1428
2 Friedman et al (1997) Am J Hum Genet 60: 313
3 Couch et al (1996) Nat Genet 13: 123
7.4
ABSENCE OF BRCA2 CAUSES GENOMIC INSTABILITY, A Tutt, A
Gabriel, D Bertwistle, F Connor, H Paterson, J Peacock, G Ross and
A Ashworth, Institute of Cancer Research, London SW3 6JB, UK
Background Women heterozygous for mutations in the breast cancer susceptibility
gene BRCA2 have a highly elevated risk of developing breast cancer. BRCA2 encodes
a large protein; and although functions in DNA repair and transcription have been
suggested, its role in breast carcinogenesis is not clear. We have previously
constructed a hypomorphic mutation (Brca2Tr2014)(1). Embryonic fibroblasts (MEFs)
derived from mice homozygous for this mutation or a similar mutation (Brca2Tr)(2)
proliferate poorly in culture, and overexpress p53 and p21Waf1/Cip1. These MEFs have
intact p53-dependent DNA damage G1/S(1, 2) and G2/M checkpoints(2), impairment
of DNA double strand break (dsb) repair(1) and develop chromosome aberrations(2).
Aim of study To further examine the role of Brca2 in the maintenance of genomic
stability at the chromosomal level, using spontaneous induction of micronuclei and
examination of chromosome segregation.
Methods MEFs at passage 2 or 3 were fixed, stained with DAPI, and at least 200
MEFs per data point were sampled from each of 3 embryos per genotype (Brca2 +/+;
Brca2Tr2014/+,  Brca2Tr2014/Tr2014) in 3 independent experiments to score micronucleus
frequency and centrosome number. Micronucleus type was scored by FISH using a
pancentromeric probe The centrosome (mitotic spindle organising centre) was
labelled with an anti-g tubulin antibody and detected by immunofluorescent
microscopy. Metaphase chromosome spreads were made using standard methods.
Results Homozygous mutation in Brca2 leads to the formation of spontaneous
micronuclei, a marker of chromosome instability. The proportion of cells containing
micronuclei increased with passage. Chromosomal missegregation was a major mech-
anism leading to formation of micronuclei, and resulted in significant aneuploidy.
Brca2Tr2014/Tr2014 MEFs developed centrosome amplification at low passage, and such
cells also contained micronuclei.
Conclusions We have demonstrated a role for Brca2 in maintenance of genomic
stability at the chromosomal level. These data suggest a mechanism whereby loss of
Brca2 may drive the loss of cell cycle regulation genes thus enabling proliferation and
tumorigenesis.
1 Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, et al (1997)
Tumorigenesis and a DNA repair defect in mice with a truncating Brca2
mutation. Nat Genet 17:(4) 423–30
2 Patel KJ, Vu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, et al (1998)
Involvement of Brca2 in DNA repair. Mol Cell 1:(3) 347–57
7.5
DIFFERENCES IN THE BIOLOGICAL AND CLINICAL EFFECTS OF
VOROZOLE AND TAMOXIFEN IN POST-MENOPAUSAL PRIMARY
BREAST CANCER C Harper-Wynne*1, K Shenton1, R Ahern1, F MacNeill2, 
P Sauven2, I Laidlaw2, Z Rayter2, S Miall2, N Sacks2 and M Dowsett1, 1The
Academic Department of Biochemistry, The Royal Marsden Hospital, London
SW3 6JJ, 2Vorozole Study Group, UK
We report serum and tumour-biomarker data from the first randomised study of
tamoxifen (T) versus an aromatase inhibitor (AI), vorozole (V), as primary therapy for
breast cancer. This was a single-blind multicentre study recruiting postmenopausal
patients with ER+ve breast tumours >2 cm diam. 53 patients were randomised, 27 to
T 20 mg/day and 26 to V 2.5 mg/day orally for 12 weeks. Serum markers of bone
resorption, measured by ELISA, decreased in the T arm after 12 weeks (p=0.006), but
did not significantly change in the V group. Tumour biopsies were performed pretreat-
ment (pre) and at 2 and 12 weeks (2 w, 12 w) for analysis of proliferation (Ki67),
apoptosis (TUNEL) and ER/PgR status. Ki67 levels decreased between pre & 2 weeks
by 58% (mean) with V (p=0.002) and by 43% with T (p=0.04): p=ns for the difference
between T & V. There were falls in Ki67 between pre & 12 w by 73% with V
(p<0.001) and by 57% with T (p=0.015), with a significant fall between 2 w & 12 w
with T (P=0.03). The data indicate a more rapid effect on proliferation with the AI but
the later fall with T (2 w–12 w) resulted in no significant difference in Ki67 reduction
between the 2 groups over the 12 weeks. Positive correlations, of borderline signifi-
cance, existed between pre-2 w Ki67 reductions and pre-12 w tumour volume reduc-
tions (T; p=0.08 & V; p=0.09). There was a significant decrease in apoptosis between
pre & 2 w in the V group (p=0.03) but with no change in the T group. Ki67/apoptosis
ratio was reduced at 2 w by 48% (mean) with T (p=0.01) and by 35% with V (ns) and
at 12 w by 63% (p=0.01) and 69% (p=0.01) respectively. Serum IGF-1, a recognised
anti-apoptotic protein, was non-significantly elevated over 12 wk in the V group and
significantly reduced in the T group (p=0.01). 
Conclusion This study indicates that V does not significantly increase bone loss in
this group over 12 weeks. The trend towards proliferation reduction at 2 w predicting
volume reduction at 12 w for V supports the use of Ki67 changes at 2 w as an inter-
mediate endpoint. Pharmacokinetic differences between drugs, however, may influ-
ence optimal timing of a biopsy to accurately predict for response. The Ki67/apoptosis
ratios were similar for both drugs, cytostatic effects predominating in determining the
clinical response. It is possible that the difference in the change in apoptosis between
the drugs relates to the different effects of T & V on IGF-1. Studies of down stream
components of this pathway as well as of bcl-2 family members are therefore being
evaluated in these samples.26 Oral Presentations
7.6
A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC
TRIAL OF THE VEGF INHIBITOR SU5416 INCORPORATING
QUANTITATIVE CONTRAST ENHANCED MR ASSESSMENT OF
VASCULAR PERMEABILITY A O’Donnell1,2, J Trigo1,2, U Banerji1,2, F
Raynaud2, A Padhani1,2, A Hannah3, A Hardcastle2, W Aherne2, P Workman2
and I Judson1,2, 1. Royal Marsden Hospital, Sutton, 2. Institute of Cancer
Research, Sutton, 3. SUGEN Inc. Sth San Francisco, USA
SU5416 (Z-3-[2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone) is a potent
inhibitor of VEGF mediated Flk1/Kdr receptor signalling. When used against a panel
of murine and human tumour cell lines in xenograft models SU5416 demonstrates
broad anti-tumour activity with reduction in total and functional tumour vasculariza-
tion and well as tumour growth inhibition. This Phase I trial investigates traditional
endpoints – toxicity and pharmacokinetics but also incorporates pharmacodynamic
endpoints – tumour vascular permeability using dynamic contrast enhanced MR and
serial VEGF levels in an attempt to provide non-invasive means of determining early
biological evidence of effect for an agent which is potentially cytostatic. Sequential
cohorts of 3 patients have received escalating doses of SU5416 twice weekly for 4
weeks per cycle. Currently 22 patients (11 M: 11 F) with a variety of tumour types,
median age 48 years (20–74 years) have received 43 cycles of SU5416 at doses: 48
mg/m2 (3 pts), 65 (3), 85 (3), 110 (3), 145 (3), 145 ® 190 (7). No dose limiting toxi-
city has been observed. Local venous thrombophlebitis is common. Despite premed-
ication, hypersensitivity reactions (attributed to the diluent Cremophor®) requiring
additional steroid administration, have occurred in 8 patients however treatment has
been able to be continued in each case. All other toxicity was mild. Headache and
emesis appear dose related. No haematologic or metabolic toxicity has been observed.
Pharmacokinetic studies show rapid drug clearance (mean 74.3 L/hr ± SD 29.5) with
the formation of two metabolites – 5¢ hydroxyl SU5416 and 5¢ carboxyl SU5416. An
increase in drug clearance with repeated administration is seen. This has enabled
intra-patient escalation in therapy from 145 ® 190 mg/m2 (190 mg/m2 reported as
DLT, Rosen ASCO 1999 Abs 618) after 4 doses with no additional toxicity. No
tumour responses have been seen however 7 patients have has stable disease with 6
remaining on study for ³ 12 weeks. Using Magnevist® enhanced MR performed 1–4
hours post dose, a decrease in permeability was seen in 4/6 patients with stable
disease. (Rg 12–37%) Conversely in 6/12 patients with progressive disease an
increase in vascular permeability was seen. (Rg 17–41%) These changes were
observed even at the lowest dose level. VEGF levels in plasma, serum and platelet
depleted plasma in patients receiving the final dose level will be correlated with these
results. Accrual is ongoing.
7.7
A PHASE I STUDY OF A 5-DAY SCHEDULE OF IV TOPOTECAN
(T) AND ETOPOSIDE (E) IN UNTREATED SMALL CELL LUNG
CANCER (SCLC) Penny Sutton*1, Peter I Clark1, David B Smith1, Ernest
Marshall1, Kate Hannigan1 and Graham Ross2, 1Clatterbridge Centre for
Oncology, Merseyside, UK and 2SmithKline Beecham Pharmaceuticals, UK
The topoisomerase I inhibitor T and the topoisomerase II inhibitor E are both active in
SCLC. The importance of sequence has not been elucidated in cancer patients (pts). A
phase I trial explored a schedule combining an intravenous (IV) 5-day regime of both
T and E in previously untreated pts with SCLC. T was given as a 30 min infusion,
followed by a 30 min saline flush and then a 1 hour infusion of a fixed daily dose of E
(60 mg/m2/day) every 3 weeks for a maximum of 6 cycles. Dose levels of T
commenced at 0.5 mg/m2/day and were escalated by 0.25 mg/m2/day per cohort. Dose
limiting toxicity was defined as 33% of pts with > Grade 3 non-haematological toxi-
city and/or absolute neutrophil count nadir <0.5´109/l for 7 days or complicated by
fever requiring IV antibiotics, and/or platelets <25´109/l. To date 19 pts have received
105 courses. Median age of pts was 68 yrs; 15 had WHO performance score (PS) 1
and 4 had PS 2; 13 had extensive disease, 6 limited disease. Seven pts were treated in
the first cohort of T 0.5 mg/m2/day (41 courses): grade 4 neutropenia was seen in 7
courses (4 pts), grade 3 neutropenia in 11 courses (5 pts) and there were 11 dose
delays in 5 patients. One episode of DLT occurred. An initial 6 pts were treated in the
second cohort of T 0.75 m/m2/day and 2 episodes of DLT occurred. As one of these
occurred in a patient who subsequently had similar toxicity following treatment with
dose-reduced CAV, an additional 6 patients were enrolled. 12 pts have received 70
courses of T 0.75 mg/m2/day; grade 4 neutropenia was seen in 24 cycles (10 pts),
grade 3 neutropenia in 26 cycles (11 pts) and there have been 19 dose delays in 8 pts.
3 episodes of DLT have occurred. There have been no toxic deaths and apart from hair
loss, non-haematological toxicity was <grade 2. All 19 pts are evaluable for response
and 18 have responded, 15 PRs and 3 CRs. The median duration of survival is encour-
aging at 9+ months.
A 5-day schedule of the IV combination of T and E given on the same day is well
tolerated and appears very active in pts with untreated SCLC. The recommended
phase II dose of a 5-day schedule of this IV combination is T 0.75 mg/m2/day and E
60 mg/m2/day. A phase I study combining the oral formulations of T and E in this 5-
day schedule is underway.
7.8
A HIGHLY ACTIVE REGIMEN FOR MALIGNANT MESOTHELIOMA
WITH NEW BIOLOGICAL DATA Mendes Ra,b*, O’Brien MERa,c,
Bromelow KVb, Gregory KRa, Norton Aa, Padhani Aa, Smith IEa, Souberbielle
BEa,b, aThe Royal Marsden Hospital, Sutton, bMolecular Medicine, King’s
College, cKent Cancer Center, Maidstone, UK
Background Intradermal SRL172 (heat-killed Mycobacterium vaccae) and chemotherapy
have been used in lung cancer and mesothelioma patients with promising results. The rational
behind the addition of intratumoral SRL172, in combination with intradermal SRL172 and
chemotherapy (mitomycin, cisplatin and vinblastine), is to provoke a pro-inflammatory
microenvironment in the tumour which may be immunosuppressive.
Methods Fifteen patients were recruited into the study in 4 cohorts. Patients were given
intratumoral SRL172 at 3 weekly intervals with chemotherapy. The intratumoral dose of
SRL172 was increased 10 fold with each cohort starting at 1 mg up to 1 mg. Intradermal
SRL172 (1 mg) was given four weekly to all patients. Patients were monitored for side-effects,
clinical and symptomatic response. Tumour assessments were done by CT scan after every 2
courses of chemotherapy. Blood was taken from patients, their spouses and their age-sex
matched controls for baseline immunological parameters (lymphocytes markers, T cell func-
tional assays (MLR, mitogenic and recall antigen stimulations) and intracellular cytokine
assays for both T cells and NK cells (IL-2, IL-4, g-INF and TNF-a). At the end of treatment,
immunological assessment were repeated on the patients.
Results Baseline haemato-immunology showed that the patients, compared to the
spouses and the age-sex controls, had lower haemoglobin levels (12.84, 13.43, 14.4 g/dl
respectively, p=0.006), high platelet count (mean 383, 237, 227 109/L; p<0.001),), high
white cell count (8.96, 6.46, 7.06 109/L; p <0.05), low lymphocyte count (1.3, 1.98, 2.1
109/L; p <0.01), low CD3+ lymphocyte count (1.03, 1.45, 1.52 109/L; p = 0.007), low CD3-
ve lymphocyte count (0.36, 0.52, 0.61 109/L; p=0.005), low CD4+CD3+ cell count (0.68,
0.89, 0.97109/L; p<0.05), low NK cell count (0.13, 0.16 0.268 109/L; p=0.04) but higher
proportion of activated NK cells expressing CD69 (8.9%, 6%, 3.3%; p <0.05). Cytokine
production (IL-2, IL-4, gamma-interferon and TNF-a for T cells, NK-T cells and NK cells)
following stimulation with PMA/ionomycin were similar between the patients, spouses and
controls. Likewise, whole blood functional assays (mitogenic, allogeneic and recall antigen
stimulation) were also similar between these 3 groups. The overall objective response rate
was 40% (6/15 PR) although the first 3 cohorts who received 1 mg to 100 mg bacilli had a
response rate of 66% (6/9) suggesting that lower intratumoral doses are more effective.
Overall symptomatic response was recorded in 57% (8/14) assessable patients. The overall
median survival is 12 months. Immunological assessments after treatment revealed that the
clinical response correlated with a decrease in platelet count. All patients appeared to have a
decrease in IL-4 producing CD3+ve lymphocytes and an increase in the proportion of acti-
vated NK cells but these 2 parameters did not correlate with response suggesting that they
are non-specific consequences of treatment.
Conclusion SRL172 can safely be given intratumorally and we have established the
intratumoral dose that is appropriate for future studies. The regimen had high response rate
and predictable toxicity profile. In addition, the simple correlation of the platelet count with
clinical response should be further investigated in mesothelioma.
We thank SR Pharma for their support.
8.1
INTENSITY-MODULATED RADIOTHERAPY (IMRT) FOR
TUMOURS OF THE HEAD AND NECK, PELVIS AND THORAX:
PRE-CLINICAL EVALUATION AND IMPLEMENTATION C Nutting*, D
Convery, V Cosgrove, C Rowbottom, S Webb, and D Dearnaley, Institute of
Cancer Research and Royal Marsden NHS Trust, Surrey SM2 5PT, UK
Purpose To evaluate the potential benefits of IMRT compared to current radiotherapy
techniques, and to implement clinical trials of IMRT for appropriate tumour sites.
Methods 30 patients with head and neck, pelvic and thoracic tumours underwent
treatment planning for conventional radiotherapy (RT), 3-dimensional conformal RT
(3DCRT) and inverse-planned IMRT. Dose distributions were compared using dose-
volume histograms for tumour and normal tissues, and normal tissue complication
probabilities were calculated. Methods were developed to optimise beam number and
direction to determine the most efficient delivery techniques, and for pelvic tumours a
clinical dose escalation trial protocol was designed.
Results IMRT treatment plans for thyroid carcinoma and pelvic lymph nodes
(tumours with a concave PTV) showed the greatest improvements compared to
conventional and 3DCRT. There was 12% reduction in maximum spinal cord dose
(p<0.01), and a 70% reduction in pelvic small bowel treated above 45 Gy (p<0.01)
respectively. PTV dose homogeneity was improved, and other normal tissues also
spared. Oesophageal, parotid, and para-nasal sinus tumours (with moderate or no
concavities in the PTV), showed statistically significant but smaller improvements in
normal tissue sparing of lungs, oral cavity and cochlea, and optic nerves respectively.
9, 7, or 5 equispaced IMRT fields gave similar benefits, but dose distributions deteri-
orated with 3 equispaced fields. A computerised optimisation algorithm was designed
which, for selected tumour sites, customised the IMRT beam directions allowing both
coplanar and non-coplanar beam arrangements. This produced novel techniques that
maintained the advantages of multi-field IMRT but using only 3–4 beams. This should
reduce the time required for IMRT delivery, and verification. Treatment plans were
delivered to humanoid phantoms using a dynamic multi-leaf collimator technique, and
the delivered doses were found to be accurate to within 1–2% using photographic film
and BANG gels. A Phase 1 clinical protocol was designed to evaluate dose escalated
IMRT (50–65 Gy) to pelvic lymph nodes while sparing small bowel. The main end-
points will be clinician and patient assessments of acute and late toxicity, recruitment
starting in April 2000.
Conclusions IMRT represents a significant advance in conformal radiotherapy.
The benefits are greatest for tumours with a concave PTV where normal tissue struc-
tures within the concavity can be spared. For non-concave tumours, dose homo-
geneity is improved compared to current techniques, and for all tumour sites some
normal tissue sparing was observed. Treatment delivery is possible with 3–5 opti-
mised beam directions, and clinical assessment of this technique is underway.Oral Presentations 27
8.2
PALLIATIVE RADIOTHERAPY FOR MUSCLE INVASIVE BLADDER
CANCER: FINAL RESULTS OF A PROSPECTIVE RANDOMISED
TRIAL OF TWO RADIOTHERAPY SCHEDULES JD Graham*, GO Griffiths,
BM Uscinska & GM Duchesne, On behalf of the MRC Bladder Cancer Working
Party MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Methods A multi-centre randomised trial was conducted comparing the efficacy and
toxicity of two radiotherapy schedules (35 Gy in 10 fractions and 21 Gy in 3 fractions)
for symptomatic improvement in patients considered unsuitable for curative treatment
through disease stage or co-morbidity. The primary outcome measures included
overall symptomatic improvement of bladder-related symptoms at 3 months and
changes in bladder and bowel related symptoms from pre-treatment to end of treat-
ment and 3 month assessments. Overall symptomatic improvement was defined as the
improvement in one-clinician-reported bladder-related symptom of at least one grade
at 3 months, with no deterioration in any other bladder-related symptom.
Results 500 patients were recruited but data on symptomatic improvement at 3
months was only available on 272 patients. Of these 68% (184/272) achieved sympto-
matic relief, 71% (95/133) for 35 Gy and 64% (89/139) for 21 Gy, a difference of 7%
95% CI (–2%, 13%), p=0.192. There was no evidence of a difference in efficacy or
toxicity between the two schedules. There was also no evidence of a difference in
survival between the two schedules (HR=0.99, 95% CI 0.82, 1.21, p=0.933).
Conclusion This is the largest prospective trial to date in the palliative treatment of
bladder cancer and provides baseline data against which other results may be
compared. The use of 21 Gy in 3 fractions appears as effective as 35 Gy in 10 frac-
tions, although modest differences in survival, symptomatic improvement rates and
toxicity cannot be reliably excluded.
8.3
BCL-2 EXPRESSION IDENTIFIES PATIENTS WITH ADVANCED
BLADDER CANCER TREATED BY RADIOTHERAPY WHO
BENEFIT FROM NEOADJUVANT CHEMOTHERAPY PW Cooke*1, R
Ganesan2, A Burton1, LS Young, DMA Wallace2, ND James1, 1. CRC Institute
for Cancer Studies, University of Birmingham, 2. Queen Elizabeth Hospital,
Birmingham, UK
Objective To assess the prognostic significance of Bcl-2 expression on the clinical
outcome after radiotherapy for muscle-invasive bladder cancer, and to determine if it
is possible to identify a subgroup of patients to whom neoadjuvant chemotherapy can
be targeted to improve survival.
Materials and Methods Immunohistochemical staining for Bcl-2 and p53 was
performed on the tumours of 51 patients with stage T2–T4a NX M0 TCC of the
bladder who had been included in a randomised clinical trial of radiotherapy with or
without neoadjuvant cisplatin. The association between positive staining and salvage
cystectomy rate and overall survival was examined, with a median follow-up of 12
years.
Results Positive Bcl-2 and p53 expression was seen in 31 (61%) and 39 (76%) of
the tumours, with no association between either or with tumour stage or grade. There
was no difference according to Bcl-2 positivity in the salvage cystectomy rate
(p=0.83) or survival (p=0.68) for the 51 patients as a whole, but Bcl-2-negative
patients receiving neoadjuvant cisplatin did have a significantly improved prognosis,
with a median survival of 72 months compared to 17 months in Bcl-2-positive
patients, and a five year survival rate of 55% (p=0.03).
Conclusions Bcl-2 quantification in patients undergoing radiotherapy for
advanced bladder cancer identifies patients who may benefit from neoadjuvant
chemotherapy. Further studies of members of the Bcl-2 family and related proteins are
warranted, to define interactions between them that may contribute to oncogenesis
and resistance to standard treatments. This may allow targeting of specific treatments
to patients known to be sensitive to them and aid the future development of novel
therapies.
8.4
CARBOGEN AND NICOTINAMIDE WITH RADICAL
RADIOTHERAPY FOR BLADDER CANCER: UPDATED PHASE II
RESULTS AND LAUNCH OF THE BCON PHASE III RANDOMISED TRIAL
PJ Hoskin*, H Phillips, S Jackson, P Wims, N Verma, MI Saunders, Mount
Vernon Hospital, Northwood HA6 2RN, UK
Carbogen and nicotinamide used as radiosensitisers to overcome chronic diffusion-
related hypoxia and acute perfusion-related hypoxia respectively have been evaluated
in a Phase II trial in bladder cancer. A total of 102 patients have been entered at 31st
January 2000 of whom 95 have completed treatment with a minimum of 6 months
follow up.
Previous analyses have demonstrated an improvement in overall survival, progres-
sion-free survival and local relapse-free survival compared to historical controls. With
a median follow up of 36 months this larger cohort of patients continues to maintain
the previously observed improvement. The 3 year overall survival is 52%. The 3 year
progression-free survival is 70% and the 3 year local relapse-free survival is 82%. No
local relapse beyond 3 years have been observed. The more recent 32 patients have
had a modified treatment with the concentration of carbogen gas changed to 2% CO2
98% oxygen compared to a 5% CO2 95% oxygen mixture and the dose of nicotin-
amide reduced from 80 mg/kg to 60 mg/kg. This was to improve compliance with the
medication and has been entirely successful with all patients tolerating carbogen
without difficulty throughout the 20 fraction radiotherapy schedule; 75% have taken
nicotinamide with > 75% of the overall treatment (ie. > 15 fractions) and 67% for the
entire treatment – this compares to only 42% taking nicotinamide 80 mg/kg
throughout in the earlier patients. No significant difference is seen between these
patients and the preceding cohort of 70 patients in local control, progression-free
survival and overall survival curves.
Detailed toxicity analyses are underway. One patient has developed Grade III
bowel toxicity and one patient has required cystectomy for a fibrosed shrunken
bladder in preference to continued catheter drainage. No other major late normal
tissue toxicity has been encountered.
Against the above background a formal Phase III trial of carbogen and nicoti-
namide in the radical treatment of bladder cancer with radiotherapy has now been
launched. This uses 2% carbogen, 60 mg/kg nicotinamide with radical radiotherapy
either 55 Gy in 20 fractions over 4 weeks or 64 Gy in 32 fractions over 6 1/2 weeks
randomised against radiotherapy alone as the control arm. This is a multicentre study
funded by the Cancer Research Campaign co-ordinated through Mount Vernon
Hospital and centres are invited to collaborate.
8.5
FINAL ANALYSIS OF THE MRC/EORTC TRIAL OF 3 VS 4 ´ BEP
AND 5 DAYS VS 3 DAYS PER CYCLE IN GOOD PROGNOSIS
GERM CELL CANCER JT Roberts, R de Wit, PM Wilkinson, PHM de Mulder,
GM Mead, SD Fossa, PA Cook, L de Prijck, SP Stenning and L Collette, For
the MRC Testicular Tumour Group, London, UK and the EORTC Genito-
Urinary Group, Brussels, Belgium
This trial was designed as a 2´2 factorial equivalence trial comparing 3 cycles of
bleomycin, etoposide, cisplatin (3BEP) versus 4 cycles (3BEP-1EP), and the adminis-
tration of BEP over 5 days versus 3 days in IGCCCG good prognosis germ cell cancer
(JCO 1997;15:594). The aim was to rule out a 5% decrease in the 2-year progression-
free survival (PFS) rate with 90% power using 1-sided tests and a=0.10. BEP
consisted of etoposide 500 mg/m2, administered at either 100 mg/m2 days 1–5, or 165
mg/m2 days 1–3, cisplatin 100 mg/m2, administered at either 20 mg/m2 days 1–5, or
50 mg/m2 days 1–2. Bleomycin 30 mg was administered on days 1,8,15, during cycles
1–3. The randomization procedure in the MRC allowed some investigators to partici-
pate only in the comparison of 3 vs. 4 cycles. Between March 1995 and April 1998,
812 patients were randomized between 3 and 4 cycles, of these 681 were also random-
ized between 5 days and 3 days. Histology, marker values, and disease extent are well
balanced in the treatment arms in the 2 comparisons. The median follow-up is 25
months, a minimum of 2 years follow-up is available for 93% of patients. The esti-
mated 2 y PFS is 90.4% on 3 cycles and 89.4% on 4 cycles. The difference in PFS
between 3 and 4 cycles is –0.99% (80% ci: –3.81% to +1.83%). Equivalence for 3 vs.
4 cycles is claimed as the upper bound of the 80% ci. is < 5%. In the 5 vs 3 days
comparison, the estimated 2 y PFS is 88.8% and 89.7%, respectively (difference –
0.92%, 80% ci: –4.1 to +2.2%). Hence, equivalence is claimed in this comparison
also. Myelotoxicity was more pronounced in the 3-day schedule (test for trend
leucopenia p = 0.014, thrombocytopenia p = 0.001), but this did not result in greater
dose attenuations. Frequencies of non-hematological toxicities were similar. We
conclude that 3 cycles of BEP, with etoposide at 500 mg/m2, is sufficient therapy in
good prognosis germ cell cancer, and that the administration of the chemotherapy in 3
days has no detrimental effect on the effectiveness of the BEP regimen.28 Oral Presentations
8.6
PACLITAXEL-CONTAINING HIGH DOSE CHEMOTHERAPY FOR
RELAPSED OR REFRACTORY GERM CELL TUMOURS
IA McNeish, EJ Kanfer, R Haynes, R Agarwal, SJ Harland, ES Newlands, MJ
Seckl, Departments of Medical Oncology and Haematology, Imperial College
School of Medicine, Hammersmith and Charing Cross Hospitals, London:
The Meyerstein Institute of Oncology, Middlesex Hospital, London, UK
Previous reports from our group1 and others2,3 have indicated that high dose regimes
containing etoposide, carboplatin and an oxazaphospharine can salvage 30–40% of
patients with relapsed or refractory germ cell tumours and produce median event-free
intervals of approximately 4 months. Since March 1995, we have treated 22 gonadal
germ cell tumour patients with CarbopEC-T, a paclitaxel-containing high dose regime
(paclitaxel 75 mg/m2, etoposide 450 mg/m2, carboplatin AUC10 on days –7, –5 and
–3 and cyclophosphamide 60 mg/kg on days –5 and –3) followed by peripheral blood
stem cell infusion (day 0). By the criteria of Beyer et al2, 15 patients had cisplatin
sensitive disease, 3 refractory disease and 4 absolutely refractory disease prior to high
dose therapy. The one year overall and event-free survival rates for all patients are
68% and 51% respectively (median follow up 12.3 months). For the 15 patients with
sensitive disease, these survival rates are 84% and 60% respectively, whilst for those
with refractory or absolutely refractory disease, the one year overall survival is 26%
with a median of 8.5 months. Six patients (response to high dose therapy: 2 CR, 4 PR)
have relapsed at a median duration of 6.3 months, five of whom have subsequently
died. One heavily pre-treated patient with a primary CNS germinoma has also
received CarbopEC-T, and achieved PR, but relapsed at 20 months. There have also
been three treatment-related deaths, all associated with pneumonitis. Pulmonary toxi-
city has previously been reported to complicate the addition of paclitaxel to other high
dose regimes4 but may be alleviated by administering the drug as a 120 hour infusion5.
In summary, we believe that CarbopEC-T may enable a greater proportion of patients
with relapsed and refractory germ cell tumours to enter long term remission.
1 Br J Cancer (1998) 77: 1672–6
2 J Clin Onc (1996) 14: 2638–45
3 Eur J Cancer (1998) 34: 1883–8
4 Blood (1997) 90: Supp 1 4356
5 Cancer (1998) 83: 1540–5
8.7
MAINTENANCE TREATMENT WITH INTERFERON FOR
ADVANCED OVARIAN CANCER G Hall*1, R Coleman2, M Stead3, E
Gurney3, A Phillips3, J Brown3, D Dassu3, A Jenkins1, S Brown2, B Hancock2,
P Selby1, T Perren1, 1ICRF Cancer Medicine Research Unit, St James’s
University Hospital, Leeds, UK; 2Weston Park Hospital, Sheffield, UK;
3Northern and Yorkshire Cancer Trials Research Unit, Leeds University,
Leeds, UK
Patients with advanced ovarian cancer respond well to initial chemotherapy but such
responses are rarely maintained, ultimately leading to the death of the patient.
Interferon-alpha has been demonstrated to have activity as a maintenance therapy in
patients with B-cell malignancies such as multiple myeloma. We have therefore
performed a multi-centre randomised controlled trial to assess the effect of low dose
subcutaneous interferon-alpha in patients with advanced epithelial ovarian cancer, in
maintaining the response achieved with primary surgery and chemotherapy and its
effect on overall survival.
Patients with epithelial ovarian cancer (FIGO stage Ic-IV) were registered within
the trial following primary surgery/biopsy and prior to the administration of
chemotherapy. The choice of chemotherapy was not dictated but the use of standard
regimens including platinum agents was advised. Following chemotherapy,
consenting patients with no evidence of disease progression were randomised to treat-
ment with interferon-alpha-2a (RoferonR–Roche) at a fixed dose of 4.5 MU subcuta-
neously on Monday, Wednesday and Friday each week or observation. Treatment was
discontinued for disease progression, toxicity or at the patient’s request.
Between February 1990 and July 1997, 559 patients were registered prior to
chemotherapy by 28 consultants. 300 (54%) patients were subsequently randomised;
149 to maintenance interferon, 151 to observation. Baseline characteristics of both
groups including age, histology, FIGO stage at presentation and performance status
were similar. 93% of patients received either single agent platinum or a platinum
containing combination. A median follow-up of 26.3 months has now been achieved.
215 (71%) patients have documented disease progression and 185 (62%) have died.
For all patients randomised no significant differences exist for overall survival
(median 26.9 months, interferon; 31.2 months observation; log rank p=0.56) or
progression-free survival (median 11.0 months, interferon; 10.8 months observation;
log rank p=0.62). Analysis of the 180 patients apparently disease-free following
surgery and/or chemotherapy shows a median progression-free survival of 16.5
months (interferon) and 14.4 months (observation).
In this relatively small study, low dose subcutaneous interferon-alpha has no
apparent benefit as a maintenance therapy in patients with advanced ovarian cancer.
8.8
MOLECULAR PROFILING OF ANGIOGENESIS AND OCCULT
MICROMETASTASES IN CERVICAL CANCER Van Trappen P,
Gyselman V, Ryan A, Lowe D, Dorudi S, Shepherd J & Jacobs I, Academic
Departments of Gynae-Oncology, St Bartholomew’s Hospital, London
(e-mail: p.o.vantrappen@mds.qmw.ac.uk)
Cervical cancers metastasize preferentially into the lymphatic system and the inci-
dence of histologically involved lymph nodes is directly related to the stage of
disease. Several prognostic factors such as microvessel density, as marker for angio-
genesis, have been implicated in lymph node (LN) involvement. However, recent
reports suggest that new lymphatic formation, lymphangiogenesis, might be crucial in
the process of lymphatic spread. Furthermore, a subgroup of patients with node-nega-
tive early stage disease will develop recurrence despite histologically normal LNs,
suggesting the presence of occult micrometastases at initial presentation.
We have therefore designed the present study to assess, by using real-time quanti-
tative RT-PCR (Taqman) for CK 19-mRNA, the incidence and amount of occult
micrometastases in 156 LNs from 32 early stage cervical cancer patients.
Furthermore, we have quantified the mRNA levels of different angiogenic factors in
the primary tumours.
Evidence suggestive of occult micrometastases was detected in 58% of histologi-
cally uninvolved lymph nodes from above patients. In the primary tumours a 10´
increase in transcription level was observed for VEGF 121 (p<0.0000002), VEGF 165
(p<0.000002), VEGF 189 (p=0.001), thrombospondin 2 (p<0.002) and eIF4E
(p<0.002). A 100´ increase was observed for MMP 9 (p<0.00004) and a 1000ts
increase for the lymphangiogenic factor VEGF C (p<0.000006). No significant upreg-
ulation was seen for bFGF and MMP2.
Our findings demonstrate the crucial role of VEGF A splice variants, VEGF C and
MMP 9 in the process of occult metastatic spread in early stage cervical cancers.